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ABSTRACT 
 
Pyrolytic Fate of the Synthetic Cannabinoids 
 
Corey Andrew Nida 
 
Since the introduction of herbal incense products into the illicit drug market, one of the 
most concerning factors has been the uncertainty regarding their health effects. Side effects 
such as anxiety/agitation, increased heartbeat, hallucinations, and suicidal tendencies are 
commonly reported with the use of products containing synthetic cannabinoid. However, a 
largely unknown toxicity and pharmacology is still associated with synthetic cannabinoids 
and long-term health effects have yet to be discussed. 
Prior scientific studies have not focused on the big-picture in terms of the pyrolysis of 
traditional drugs of abuse that are smoked or the relatively new synthetic cannabinoids. 
Numerous agencies and statistics have reported the number of health-related incidents 
regarding the use of synthetic cannabinoids, but there has yet to be peer-reviewed reports 
seeking to understand what caused these health effects. Therefore, the purpose of this 
research was to investigate the pyrolytic fate of JWH-018, JWH-030, JWH-081, and UR-144 
and the smaller components which comprise these synthetic cannabinoids. 
Studying a number of the most common components that comprise a large number of 
the synthetic cannabinoids allows for a broad-ranging, cost-effective dissemination of 
results. A comprehensive approach was taken for identifying the pyrolytic products 
observed with a series of indole and naphthalene containing compounds. In doing so, a 
baseline of pyrolytic products that can form was established and it was found that a number 
of polyaromatic hydrocarbons, heterocyclic amines, and other hazardous or potentially 
hazardous compounds were generated. 
Analysis of the synthetic cannabinoids in this study showed that known carcinogenic 
compounds and potentially harmful pyrolytic products, such as carbazole, naphthalene, and 
benz[a]anthracene, are generated during smoking. The synthetic cannabinoids JWH-071 
and JWH-018 were also, respectively, identified as pyrolytic products of JWH-018 and 
JWH-081. Furthermore, a number of compounds that were not identified have been 
reported which may, like the additionally generated synthetic cannabinoids, also retain 
activity at the cannabinoid receptors. 
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CHAPTER 1: INTRODUCTION 
1.1.0 PURPOSE 
 
As a consequence of the sheer number of new synthetic cannabinoids that are 
continually being introduced into the illicit drug market, most forensic laboratories 
struggle to keep pace with sample analysis. The unfortunate situation that currently 
exists in the forensic community has hindered the ability of laboratories to focus on 
fundamental research in the context of synthetic cannabinoids. As synthetic 
cannabinoids are usually ingested by smoking, the chemical reactions and pyrolytic 
products of smoking are of interest. Therefore, the purpose of this research is to better 
understand the pyrolytic chemistry that occurs upon the burning of a select number of 
synthetic cannabinoids (JWH-018, JWH-030, JWH-018 and UR-144) under cigarette-
like temperatures and conditions. 
The value of such research spans many scientific fields. In general, the pyrolysis of 
drug molecules is poorly understood at best [1]. As such, the experimental research on 
this subject area can provide benefit to: (1) chemists interested in the mechanistic 
understanding of organic synthesis and reaction mechanisms present at high 
temperatures (greater than ~350°C); (2) forensic toxicologists interested in the 
potentially new markers of exposure/abuse that can be sought in biological specimens 
for added forensic value; and (3) pharmacologists interested in investigating the 
cannabinoid receptor activity and competitive binding implications that such pyrolytic 
products may produce. 
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1.2.0 BACKGROUND 
 
Cannabinoids can be defined as a diverse group of chemical compounds that exert 
pharmacological effects via the endocannabinoid system present in our bodies. The 
word ‘group’ has been purposefully selected to describe the category of cannabinoids 
because these compounds do not necessarily conform to a set of rigid structural 
similarities. There have been various attempts to categorize cannabinoids into given 
sub-categories, such as phytocannabinoids (plant-derived), endocannabinoids 
(endogenous) and synthetic cannabinoids. However, when discussing cannabinoids it is 
more appropriate to use the term “cannabimimetic” (Originating from the Cannabis plant 
and the Greek element mimetic, meaning ‘to imitate’). Cannabimimetics exert effects 
similar to the primary psychoactive constituent found in marijuana, Δ9-
tetrahydrocannabinol (Δ9-THC, Figure 1). 
 
 
1.3.0 BASIC UNDERSTANDING OF THE ENDOCANNABINOID SYSTEM 
 
The endocannabinoid system is an extensive signaling system that consists of 
receptors (specifically, the cannabinoid receptors), their corresponding endogenous 
 
Figure 1: IUPAC numbering system and molecular structure for Δ9-tetrahydrocannabinol 
(Δ9-THC) 
3 
 
 
substrates (known as endocannabinoids), and the enzymes responsible for the 
production and degradation of these endogenous substrates [2]. Breakthroughs in the 
late-1980’s and early to mid-1990’s significantly helped progress the scientific 
understanding regarding the endocannabinoid system, but substantial work remains to 
be done. 
The discovery of the CB1 and CB2 cannabinoid receptors in 1988 and 1993, 
respectively, led to an immense amount of interest and research that is continuing [3, 4]. 
These discoveries and the subsequent ability to clone the cannabinoid receptors led 
researchers to look for the endogenous substrates. In 1992 and 1995, researchers 
identified two endocannabinoids: N-arachidonoylethanolamine (anandamide or AEA) 
and 2-arachidonoylglycerol (2-AG) (Figure 2) [5, 6]. 
 
 
The location of the CB1 and CB2 receptors in our bodies are known. The CB1 
receptor is highly abundant in the central nervous system (CNS) but is also found in the 
peripheral nervous system. Conversely, the CB2 receptors appear to be localized in the 
immune system [2, 4, 7, 8]. Given the location of these receptors, there have been many 
O
N
H
OH
  
Figure 2: Structures of the N-arachidonoylethanolamine (AEA, left) and 2-
arachidonoylglycerol (2-AG, right) 
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proposed physiological functions of the endocannabinoid system. Reports indicate that 
the endocannabinoid system is involved in the body’s response to and/or regulation of 
pain, inflammation, appetite, cognition, and memory and motor function [9 - 17]. 
Synthesizing potentially lucrative drug molecules aimed at modulating various parts of 
the endocannabinoid system for specific purposes has resulted in numerous molecular 
permutations of cannabinoids.  
1.4.0 THE DISCOVERY AND EVOLUTION OF CANNABINOIDS: FROM PLANTS TO 
SYNTHETICS 
 
Before the discovery of the endocannabinoid system and its receptors, a collection 
of specific behavioral side-effects (including analgesia) were the benchmark for 
identifying molecules as “cannabinoids”. In fact, the structural elucidation of Δ9-THC, the 
primary psychoactive component of Cannabis, did not occur until the mid-1960’s [18]. 
While it may seem very surprising, given that marijuana has been used in many cultures 
as a form a medicine for centuries, researchers were hindered by the lack of 
instrumental and technological tools which ultimately made the discovery possible. 
Following this revelation, the commercial availability of Δ9-THC provided researchers 
with the ability to conduct experiments aimed at understanding the pharmacology, 
metabolism, and structure-activity relationship of one of the most widely used drugs in 
the world. Additionally, there was a large amount of interest from the pharmaceutical 
industry. 
Multiple discoveries occurred in the 1970’s that served as the basis for interest in 
creating synthetic cannabinoids. At the beginning of the decade, researchers had 
identified the major metabolite of Δ9-THC as 11-hydroxy- Δ9-tetrahydrocannbinol (11-
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OH-Δ9-THC) (Figure 3) [19]. Merely finding this metabolite was not the most interesting 
part of this discovery. It was later reported that 11-OH-Δ9-THC was a more potent 
analgesic in mice than Δ9-THC (parent compound) [20]. The analgesic capability of 11-
OH-Δ9-THC sparked interest within the scientific community about what other 
cannabinoid metabolites or analogs might possess similar biological activity. 
 
 
 
 
Shortly thereafter, results documenting the behavioral effects and analgesic 
properties of some of the first synthetic cannabinoids surfaced [21, 22]. This particular 
group of synthetic cannabinoids, the 9-nor-9-hydroxyhexahydrocannabinols, contained 
slight modifications to the molecular structures of both Δ9-THC and 11-OH-Δ9-THC. 
Arguably the most significant finding from this work was that 9-nor-9ß-
hydroxyhexahydrocannabinol (HHC, Figure 4) showed analgesic potency in mice that 
was similar to that of 11-OH-Δ9-THC and morphine (Figure 5) [22]. Compared to Δ9-
THC, HHC lacks the double bond between the C-9 and C-10 positions and a hydroxyl 
replaces the C-9 methyl group. 
 
 
Figure 3: Structure of 11-hydroxy-Δ9-THC (11-OH- Δ9-THC), a metabolite of Δ9-THC 
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While the structural modifications of HHC appear minimal, the importance of these 
synthetically prepared analogs should not be overlooked. Prior to the Wilson et. al. 
work, much of the cannabinoid research was largely focused on phytocannabinoids and 
as will be evident in the following sections, a large emphasis was placed on 
synthetically designing cannabinoids from this point forward [22]. 
In the 1980’s there were many reports of newly created synthetic cannabinoids that 
differed drastically from the classical structure of phytocannabinoids found in marijuana. 
 
 
Figure 4: Structure of 9-nor-9ß-hydroxyhexahydrocannabinol (HHC) 
 
Figure 5: Structure of morphine 
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During 1970’s and 1980’s, Pfizer-Central Research pioneered efforts to create a newly 
defined analgesic pharmacophore (necessary structural features of a pharmacological 
class of molecules) that would be distinctly different from morphine and the other 
traditional opioid analgesics [23]. This initiative was a direct result of the reported 
analgesic effects of 11-OH-Δ9-THC, HHC, and Δ9-THC. While Pfizer desired to 
synthesize a compound possessing only the structural features of cannabinoids needed 
to retain the analgesic properties, but eliminate those causing the psychoactive 
properties of Δ9-THC, Pfizer inevitably created a number of compounds which retained 
those unwanted effects. 
In an attempt to identify an analgesic-cannabinoid pharmacophore, the group at 
Pfizer initially investigated the effects of structural modifications made to the 
benzopyran, phenolic group, and the lipophilic C-3 of the A-ring, (see Figure 1) for side 
chain moieties of cannabinoids. All Pfizer-Central Research compounds have a 
company-associated abbreviation (“CP”) that is listed before a series of numbers and is 
presumably a reference to Charles Pfizer, who was one of the original founders of 
company. Some of the first reported non-opioid analgesics to come as a result of this 
work were the compounds Nantradol (also known as CP-44,001-1) [23, 24] and 
Levonantradol (also known as CP-50,556-1, Figure 6) [25, 26]. 
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Compared to cannabinoids, which contained the characteristic benzopyran moiety 
and alkyl C-3 side chain, levonantradol instead contains a benzoquinoline moiety and a 
larger C-3 side chain that possesses an aromatic ether. While levonantradol is an 
analgesic derived from the cannabinoid structure, it was actually found to be more 
potent than morphine. Furthermore, experimental evidence suggests that levonantradol 
was not acting upon the opioid receptor. Unlike opioid analgesics which were known to 
be blocked by naloxone (opioid antagonist) the analgesic potency of levonantradol was 
unaffected by the antagonist. With the distinctly different structural features that 
levonantradol possessed, in relation to cannabinoids, and the evidence that they were 
not acting at the opioid receptor, Pfizer then investigated the hypothesis that 
cannabinoids and opioids were indeed acting at different biological sites. 
Further work pursued additional structural modifications that led to a signficant 
discovery in the science of cannabinoids. The molecule CP-47,497, which lacked a 
tricyclic-based structure altogether, was proposed to be a molecule possessing the 
bare-minimum structural features required to retain non-opioid analgesic effects [27, 28, 
29]. 
 
Figure 6: Structure of levonantradol (CP-50,566) 
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Compared to Δ9-THC, CP-47,497 appears radically different: it contains a slightly 
larger lipophilic C-3 side chain (1,1-dimethylheptyl moiety), does not contain a pyran 
moiety that Δ9-THC was known for and, like HHC, it also lacked both the C-9 methyl 
substituent and C-9 double bond. Similar to Levonantradol, CP-47,497 was found to be 
unaffected by naloxone and further supported the belief that the analgesic effects of 
cannabinoid-based molecules and the opioid analgesics were acting at different 
biological sites. However, it was also discovered that CP-47,497 was an even more 
potent cannabimimetic than Δ9-THC [27]. With the numerous unwanted side-effects that 
would inevitably accompany the desired analgesic effect of CP-47,497, research 
continued forward in hopes of finding a new therapeutically-beneficial drug molecule. 
In the mid to late-1980’s, Pfizer published cannabimimetic effects of two more potent 
CP molecules: CP-55,244 and CP-55,940 (Figure 8) [30]. Both of these molecules 
exceeded the potency of levonantradol (CP-50,566-1) and continued to challenge the 
current understanding of what structural features were deemed as necessary to invoke 
cannabinoid-like effects. CP-55,244 differs slightly from CP-47,497 in that it contains an 
additional ring structure with a hydroxy methane substituent. CP-55,940 also lacked the 
 
Figure 7: Structure of CP-47,497 
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pyran moiety and possessed the 1,1-dimethyheptyl moiety but differed from CP-55,244 
in that instead of an additional cyclic component, it contained a propanol functional 
ground appended to the ‘B-ring’. As much as the developments revealed by Pfizer were 
historically significant in the context of cannabimimetics, not all major revelations were 
the result of structural modifications to cannabinoid-like molecules. 
 
 
 
In the late 1980’s and early part of the 1990’s, researchers at the pharmaceutical 
company Sterling Drug (Sterling-Winthrop Research) were also working on the 
development of a potent non-opioid based analgesic [31]. As was the case with the Pfizer 
synthesized compounds, compounds beginning with “WIN” and followed by a series of 
numbers are those that originated in the Sterling-Winthrop Research group. However, 
 
Figure 8: Structures of CP-55,244 (top) and CP-55,940 (bottom) 
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the focus at the time was to create a more potent, non-acidic, non-steroidal anti-
inflammatory drug (NSAID). Therefore, instead of deriving their drug compounds from a 
cannabinoid-based molecule, work at Sterling-Winthrop sought to structurally modify the 
NSAIDs indomethacin and clometacin (Figure 9) [32]. Researchers disclosed that the 
compound known as pravadoline (WIN-48,098) (Figure 9) produced analgesic effects 
but that when compared to both morphine and NSAIDs, deviations from expected 
results were observed [33]. Like some of the previously mentioned synthetic 
cannabinoids, the efficacy of pravadoline was unaffected by the antagonist naloxone: 
indicating that it was not acting at the opioid receptor like morphine. Additionally, the 
potency of pravadoline distinguished it from other known NSAIDs. Taken together with 
the (at the time) current discoveries of the endocannabinoid system, investigations into 
the cannabinoid receptor activity of pravadoline and its analogs was a natural area of 
research to explore. 
 
 
 
Figure 9: The NSAID molecules, indomethacin (left) and clometacin (center), from which 
Sterling-Winthrop Research ultimately developed pravadoline (WIN-48,098; right) 
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Structurally, pravadoline contains an indole-core with an N-morpholinoethyl moiety, 
a 2-methyl substituent, and a methoxybenzene bridged to the indole at the C-3 position 
by a carbonyl group. A series of analogs, based upon the features of pravadoline, were 
synthesized to investigate the existence of a new cannabimimetic pharmacophore and 
can be found in Figure 10 [32]. One of the most potent cannabinoids ever created, WIN-
55,212-2 (Figure 11), came as a result of this research and became the prototypical 
compound for a new class of cannabimimetics known as amminoalkylindoles (AAI). The 
Sterling-Winthrop Research group proposed that the indole nucleus, N-aminoalkyl side 
chain, and C-3 aromatic moiety appended to the indole by a carbonyl group were 
essential features of this AAI class of cannabinoids. 
 
 
 
 
 
Figure 10: Examples of core structures used by Sterling-Winthrop to create numerous 
aminoalkylindole synthetic cannabinoids 
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Throughout the 1990’s, there were hundreds of cannabinoid receptor agonists (both 
CB1 and CB2) synthesized by lead researcher John W. Huffman of Clemson University. 
All synthetic cannabinoids made by this research group have the prefix “JWH” before 
the corresponding numerical code. Huffman’s research was heavily focused on using 
molecular modeling capabilities that allowed the research group to compare the three-
dimensional/conformational similarities that existed between more traditionally derived 
cannabinoids, such as Δ9-THC and CP-55,490, and AAIs, including WIN-55,212. It was 
found that the aminoalkyl portion of the recently reported AAI class of cannabinoids was 
not essential and instead a four to six membered alkyl side chain maximized 
cannabinoid receptor affinity [34, 35].  
 
Figure 11: Structure of WIN-55,212 
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Additional cannabinoid derivatives based upon pyrrole and indene cores led to 
hypotheses about the receptor-binding mechanisms of cannabinoid receptors. For 
instance, the proposition that certain molecular side-groups enhanced binding affinity 
through hydrogen bonding interaction with the receptors was challenged with the 
development of high-affinity indene molecules. Instead of hydrogen bonding 
interactions, Huffman proposed that agonist affinity was more directly related to 
aromatic stacking between the cannabinoid molecule and corresponding receptor [36 - 38]. 
There are too many JWH compounds (not all of which structurally resemble one 
another) to discuss in detail. For simplicity purposes, the molecular cores for which 
many common JWH compounds were based upon are illustrated in Figure 12 and the 
JWH synthetic cannabinoids studied in this research project are shown in Figure 13. It 
is worth noting that the hundreds of JWH compounds were largely synthesized for the 
purpose of better understanding the cannabinoid receptors [39]. The multiple molecular 
combinations of cannabimimetics that have been investigated by Huffman’s group had 
significantly advanced the understanding of structure activity relationships pertaining to 
both cannabinoid receptors. 
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Synthesis of cannabinoids has continued into the 21st century and unique structural 
modifications continue to be reported and observed. Researchers at Abbott 
Laboratories created a series of analogs (Figure 14) to investigate the cannabimimetic 
potential of various cycloalkyl and side-chain modifications to the indole and ketone 
moieties of the indolyl-core stemming from earlier studies out of the Sterling-Winthrop 
 
 
Figure 12: Examples of core structures used by Huffman to create numerous synthetic 
cannabinoids; naphthoyl indole (left), naphthoyl pyrrole (center), and naphthyl indene (right) 
 
 
Figure 13: Structure of JWH-018 (left), JWH-081 (center), and JWH-030 (right) 
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and Huffman research laboratories [40, 41]. One of the most potent molecules from this 
class of compounds was the synthetic cannabinoid UR-144 (Figure 15) [42]. Due to both 
its popularity and structural similarity to the JWH compounds being investigated, UR-
144 was included as the fourth and final synthetic cannabinoid of this project. 
 
 
 
 
 
 
Figure 14: Examples of core structures used by Abbott Laboratories to create numerous 
Indol-3-yl synthetic cannabinoids 
 
 
Figure 15: Structure of UR-144 
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1.5.0 GLOBAL IMPACT AND LEGAL STATUS OF SYNTHETIC CANNABINOIDS 
 
Synthetic cannabinoids under the brand-names “Spice” and “K2” were first reported 
in Europe in the mid-2000’s. Manufacturers of K2 and Spice initially sold the majority of 
their products via online retailers, advertising them as incense or an ‘herbal incense’ 
(mixture of natural herbs) that was “not intended for human consumption” [43 - 46]. 
However, in 2008, German and Austrian laboratories analyzed a set of seized Spice 
products and detected the presence of JWH-018, leading them to conclude that the 
ingredients listed on the package did not accurately describe the contents. Subsequent 
investigations by authorities in Germany, the United States, the United Kingdom, 
Denmark, Finland, and the Netherlands also indicated the presence of CP-47,497, the 
CP-47,497 C8 homolog, HU-210, JWH-073, and JWH-398 in various seized Spice 
products all of which were not listed as ingredients on the packaging [44]. 
Soon after the report detailing the true active ingredients of K2 and Spice was 
published, an influx of products containing synthetic cannabinoids appeared on the 
market [45, 47]. The availability of such products and their popularity resulted in increased 
reports by poison control centers and hospitals within the U.S. of individuals believed to 
have consumed synthetic cannabinoids. Prior to March 2010, there were an estimated 
112 reports to the American Association of Poison Control Centers (AAPCC) involving 
synthetic cannabinoids [48]. By the end of 2010, a total of 2,906 suspected cases were 
reported nationwide and in 2011, this number further increased to 6,956 incidences [49]. 
There have been no fewer than 2,600 reports involving synthetic cannabinoid per 
calendar year to the AAPCC since 2010. Table 1 shows the reported number of 
incidents per year for the past five years. This escalation of reported calls was not 
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isolated within the U.S. as a study conducted in the United Kingdom in 2011 showed 
that banned synthetic cannabinoids continued to be used in various products within the 
country [50]. 
 
Table 1: American Association of Poison Control Center statistics on reported incidents 
attributed to synthetic cannabinoid use [48] 
Calendar Year Number of Reported Incidents 
2010 2,906 
2011 6,968 
2012 5,230 
2013 2,668 
2014 3,680 
2015 4,109 through June 24, 2015 
 
 
The primary route of ingestion for synthetic cannabinoids is inhalation. Inhalation is 
accomplished by rolling the dried leaf matter and smoking as a user would smoke 
marijuana or a cigarette. In comparison, oral consumption typically results in lesser 
effects, potentially due to rapid and extensive first-pass metabolism which decreases 
the effective concentration in the blood. On the other hand, inhalation of the smoked 
drug results in rapid absorption into the bloodstream via the lungs. The rapid 
bioavailability that ensues from smoking synthetic cannabinoids coupled with their high 
affinity for CB1 receptors can result in a greater likelihood of overdoses in users, 
particularly first time users. The enhanced affinity for the CB1 receptors that synthetic 
cannabinoids possess also presents its own pharmacological effects. 
19 
 
 
Although synthetic cannabinoids bind to the same cannabinoid receptors as Δ9-THC, 
these designer drugs appear to have significant risks to users that are not observed with 
the use of marijuana [43, 44, 51 - 54]. Likely a consequence of the enhanced binding affinity 
that synthetic cannabinoids possess, adverse symptoms including but not limited to 
seizures, convulsions, increased and irregular heartbeat, depression, extreme anxiety 
leading to suicide, and the onset of psychotic episodes have been reported by 
emergency personnel [43, 48, 55 - 58]. 
Due to the increased rate at which synthetic cannabinoid incidents were being 
reported to hospitals, emergency rooms and poison control centers, legislative action 
was required. On March 1, 2011 the United States Drug Enforcement Administration 
(DEA) exercised its emergency capability to temporarily regulate the most commonly 
reported synthetic cannabinoids. In doing so, the DEA temporarily placed five synthetic 
cannabinoids (JWH-018, JWH-073, JWH-200, CP-47,497 and the C8 homolog of CP-
47,497) into the Schedule I category under the Controlled Substances Act (CSA), 
finding it necessary to “avoid an imminent hazard to the public safety” [43, 48, 59, 60].  
While placing these compounds into Schedule I was a temporary provision, its legal 
implications and benefit to society should not be overlooked. Schedule I drugs are 
classified as substances which “have a high potential for abuse, no currently accepted 
medical use in treatment in the United States, and a lack of accepted safety for use of 
the drug under medical supervision”. Such substances include heroin, lysergic acid 
diethylamide (LSD), and gamma-hydroxybutyric acid (GHB). Schedule I status also 
allows law enforcement and the DEA to fully impose criminal, civil, and administrative 
penalties, sanctions, and regulatory controls on the manufacture, distribution, 
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possession, importation, and exportation of these synthetic substances [48, 61]. 
Additionally, the emergency action provided the DEA and Department of Health and 
Human Services (HHS) time to gather more scientific evidence and approval that would 
ultimately be used to construct a permanent legislative decision regarding synthetic 
cannabinoids. 
On July 10, 2012 President Obama signed into law Senate Bill 3187 which is 
formally entitled the Food and Drug Administration Safety and Innovation Act (FDASIA). 
Though it is commonly referred to as the “Synthetic Drug Abuse Prevention Act of 2012” 
(SDAPA), this ruling permanently placed 26 designer drugs into Schedule I of the CSA 
[62]. Among the 26 designer drugs listed, fifteen are synthetic cannabinoids, including 
JWH-018 and JWH-081. Additionally, the term cannabimimetic agent was specifically 
defined in a legal context as “any substance that is a cannabinoid receptor type 1 (CB1 
receptor) agonist as demonstrated by binding studies and functional assays within 
(given) structural classes…” [63]. This ruling sought to address the growing concern 
regarding the recent popularity of various herbal incense products marketed as “legal 
highs” and combat the possession, sale, distribution, and use of such products. 
However, illicit synthetic chemists continue to manufacture new ‘generations’ of 
synthetic cannabinoids that are not specifically included in this legislative action. 
Many of the newer ‘generations’ of synthetic cannabinoids structurally differ enough 
from those listed in the SDAPA that new legislative actions need to continue to be taken 
to control the influx of new synthetic cannabinoids. For example, the synthetic 
cannabinoid UR-144 (which is being studied in this project) was temporarily placed into 
Schedule I status (along with XLR-11 and AKB-48) on May 16, 2013 [64]. Four more 
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synthetic cannabinoids (PB-22, 5-fluoro-PB-22, AB-FUBINACA and ADB-PINACA) were 
temporarily placed into Schedule I status on January 10, 2014; followed by another 
three (AB-CHMINICA, AB-PINACA and THJ-2201) on December 19, 2014 [65, 66]. Figure 
16 helps illustrate some of the deliberate structural modifications that have been made 
to avoid legislative control. 
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Figure 16: Structures of the synthetic cannabinoids specifically listed in Schedule I of the 
CSA through DEA temporary emergency scheduling in 2013 and 2014 
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Naming of many of these compounds is not as clear as the CP, WIN and JWH 
series. It has been suggested that the APICA, APINACA, CHMINACA abbreviations 
stem from the IUPAC naming of the chemical. On the other hand, AKB-48 is the name 
of a popular Japanese girl band that has been compared to the British girl band the 
Spice Girls and thus appears to be a comedic reference to the original herbal incense 
brand ‘Spice’. However, XLR-11 is the first liquid-fuel rocket engine developed in the US 
and its name could be a nod to the “high” user’s experience [67]. 
It is important to note that these are just some of the synthetic cannabinoids which 
have been identified in recent years and caught the attention of law enforcement 
agencies. According to the National Forensic Laboratory Information System (NFLIS), a 
reporting system comprised of over 300 state and local laboratories, 33,096 synthetic 
cannabinoid drug reports were documented in 2012 and 35,101 in the year 2013 [68, 69]. 
Additionally, the United Nations Office on Drug and Crime (UNODC) Global Synthetics 
Monitoring: Analyses, Reporting and Trends (SMART) Programme, which provides 
statistics on all types of new psychoactive substances (NPS), has indicated an increase 
in the number of synthetic cannabinoids appearing on the illicit drug market since 2009 
[70]. Figure 17 has been reproduced with permission from the UNODC Global SMART 
Programme and depicts the total number of NPS as well as the significant number of 
new synthetic cannabinoids that continue to be identified per year.  
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According to these global statistics, synthetic cannabinoids represented nearly 38% 
of the compounds in this highly dangerous category of drug in 2014; a 13% increase 
from five years prior, in 2009. This trend is particularly troublesome because as targeted 
legislation has been enacted to control such substances, more and more continue to 
appear on the illicit drug market. 
1.6.0 CONCLUSION 
 
With the structural elucidation of Δ9-THC in the mid 1960’s came a wave of interest 
regarding the potentially therapeutic benefits of it and other cannabinoids found in 
marijuana. The desire to develop a new non-addictive analgesic drug molecule that 
could replace morphine ultimately led to the creation of some of the first reported 
 
Figure 17: Overall number of new psychoactive substances (red) and synthetic 
cannabinoids (blue) 
*values are estimated based upon the UNODC Global SMART Update 2015 [70] 
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synthetic cannabinoids. Furthermore, the discovery of the CB1 and CB2 receptors of the 
endocannabinoid system in the early 1990’s led to the development of many synthetic 
cannabinoids. 
Parallel to the pursuit of the therapeutic benefits of the endocannabinoid system, 
synthetic cannabinoids have emerged as one of the most dangerous categories of 
designer drugs. While a number of these compounds are discarded pharmaceutical 
drug candidates, others appear to come from illicit synthetic chemists. Due to the large 
number of compounds being identified on an annual basis, the primary focus regarding 
synthetic cannabinoids has largely revolved around developing methods to detect and 
legally regulate a continually changing class of chemicals. Combined with the 
essentially unknown long-term health effects of abusing cannabinoid receptor agonists 
and antagonists, synthetic cannabinoids are firmly regarded as one of the largest 
forensic problems. 
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CHAPTER 2: PYROLYSIS AND EXPERIMENTAL DESIGN 
2.1.0 INTRODUCTION 
 
According to the International Union of Pure and Applied Chemistry (IUPAC), 
pyrolysis is defined as “a chemical degradation reaction that is caused by thermal 
energy” [71]. Pyrolysis is routinely used in the processing of oil and coal, the disposal of 
wastes, and the production of various solvents and polymers [69]. Two major concerns 
regarding pyrolysis revolve around the health and environmental impact unwanted by-
products may pose. While it will be discussed in greater detail later, it is worth noting 
that many polyaromatic hydrocarbons (PAHs) and heterocyclic amines (HCAs) can be 
generated via pyrolysis. These include some of the most well documented harmful and 
potentially harmful constituents (HPHCs) and carcinogens. The Environmental 
Protection Agency (EPA), Food and Drug Administration (FDA), and the Agency for 
Toxic Substances and Disease Registry (ATSDR) have each highlighted a number of 
PAHs as chemicals that are reason for major concern to the environment and human 
health [72 - 74]. 
Pyrolysis is often applied in forensic chemistry to analyze paints, polymers, fibers, 
and controlled substances [1, 76]. While inhalation is a common route of administration for 
many controlled substances, including synthetic cannabinoids, few peer-reviewed 
publications have fully investigated all the pyrolytic products that are formed via 
smoking. A handful of publications have studied the impact of heat on synthetic 
cannabinoids as it pertains to thermal degradation in the injection port of a gas 
chromatograph [77, 78]. Other work has sought to identify the presence of a given parent 
molecule in biological fluids after smoking a product containing one or more synthetic 
27 
 
 
cannabinoids [79, 80]. At the time of this work, however, there have not been any reports 
detailing a “big-picture” of what happens during the smoking of synthetic cannabinoids. 
Given the rate at which synthetic cannabinoids are being detected by laboratories and 
reported by emergency and law enforcement personnel, it is important that scientific 
insight be provided regarding the reality of smoking these substances. 
Underlying questions of what occurs during smoking of these compounds helped 
drive the work of this research project and attracted interest from the Drug Enforcement 
Administration and other researchers. While it has been documented that a number of 
synthetic cannabinoids possess greater affinity for the CB1 receptor than Δ9-THC, 
scientific results regarding the effects of pyrolytic products have not been established. 
Curiosity as to what, if any, structurally similar pyrolytic products may be created upon 
smoking drove this research. Isomeric variations, analogs, and molecular cores of the 
given parent molecules themselves could be biologically active at CB1 receptors. If this 
were found to be true, consequences of mixture toxicity would be at stake and of great 
importance to those interested in the public health aspects of this research. Additionally, 
some of these products may be detrimental compounds such as HPHCs that are known 
to be formed via cigarette smoking [74].  
Interest in identifying pyromarkers was another motivation behind this research. 
Screening assays for synthetic cannabinoids are in constant need of adaption to stay 
relevant. Depending upon the uniqueness of the pyromarkers, certain compounds may 
warrant incorporation into the screening assays for the synthetic cannabinoids being 
examined. The ability to expand screening assays would ultimately lead to better means 
of detection when it comes to synthetic cannabinoids. 
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2.2.0 THE CHEMISTRY OF PYROLYSIS: BONDS, RADICALS AND REACTIONS 
 
Since organic compounds have limited thermal stability, heating of an organic 
substance beyond a certain temperature induces thermal changes to the molecular 
structure. At the time of its inception, pyrolysis was used primarily to describe such 
reactions occurring in an inert atmosphere (i.e. absence of oxygen, etc.). However, now 
the term is commonly used to describe reactions occurring above approximately 300°C 
- 350°C, in either an inert or non-inert environment, while the term thermal degradation 
is used to describe processes below this temperature range. As such, the work being 
conducted in this project is best categorized as pyrolysis. 
Although pyrolysis comes from the Greek elements ‘pyro-’, meaning fire, and ‘-lysis’, 
meaning loosening, separating, or breaking down, there is a great deal of chemical 
complexity in the process that is not directly inferred from this definition. The literal 
interpretation of pyrolysis might suggest that only smaller components are generated 
from a parent molecule (i.e. degradation). However, compounds with a higher molecular 
weight than the parent(s) are often created during the process. 
The generation of complex molecular species can be attributed to subsequent 
interaction(s) between the fragments resulting from decomposition of the initial 
compound, usually via radical reaction mechanisms. Some of the radical fragments that 
appear to play a significant role in the formation of PAHs and HCAs (both of which are 
of specific interest) are acetylene, vinylacetylene, butadiene, cyclopentadiene, methyl 
cyclopentadiene, and indene. These particular fragments are capable of interacting with 
larger fragments or products and thereby creating larger radical species. These larger 
radicals can undergo a termination reaction, which effectively creates a large molecular 
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weight product, or can undergo further reactions and ultimately create even larger 
molecular weight products [81]. 
2.2.1 BOND DISSOCIATION ENERGY 
 
Bond dissociation energy (D) is the amount of energy required to break a given bond 
and is typically reported in kilojoules (kJ). The greater the bond dissociation energy, the 
stronger the bond is and therefore the less likely it is to break. Tabulated values of bond 
strengths (like those listed in Table 2) which only list the atoms that make up the bond 
itself can serve as a general guide to understanding the relative strength of the bonds in 
a molecule. The true strength of a bond is influenced by other factors such as the 
neighboring atoms and the presence of conjugation within the molecule. Nonetheless, 
when evaluating a molecular structure, bond strengths can give an indication of where a 
radical mechanism may originate based upon which bonds are more likely to break first 
(weakest bonds). From Table 2, we can see that the carbon – nitrogen single bond (C – 
N) is relatively weak when compared to some of the more common bonds present in 
organic molecules. As such, this implies that C – N bonds would be more likely to break 
first. However, such bonds would not be the only ones to break and it is helpful to avoid 
falling into that misconception. With the amount of thermal energy that is present in 
pyrolysis, a large number of bonds could be susceptible to breaking. 
 
 
 
 
 
 
 
 
 
30 
 
 
 
 
Table 2: Bond energy values for common organic constitutents [82] 
Constituents of 
Bond 
Average Bond 
Dissociation 
Energy (kJ/mol) 
Constituents of 
Bond 
Average Bond 
Dissociation 
Energy (kJ/mol) 
C – N 293 H – H 436 
C – C 348 C = C 614 
C – H 413 C = O 743 
 
 
 
2.2.2 RADICAL REACTIONS 
 
Radical (chain) reactions readily occur during pyrolysis and as with all radical-based 
reactions, the concepts of initiation, propagation, and termination are important for 
understanding how such a mechanism occurs (see Figure 18). An initiation step in the 
chain reaction is where a radical product is generated from a non-radical containing 
reactant(s). In organic compounds, radicals can be easily generated during pyrolysis via 
homolytic bond cleavage (radical splitting), particularly hydrogen abstraction and/or 
scission reactions [81]. A propagation step in the reaction is one in which a radical 
reactant generates a radical product, while termination involves two radical reactants 
producing a non-radical containing product.  
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Generally speaking, the products formed as a result of a termination step tend to rely 
heavily upon the ability of the propagation steps to create radicals. In pyrolysis though, 
initiation steps can have a more pronounced effect on the products formed because the 
high temperature enables more radicals to be generated via initiation than other 
reactions. This increased role of initiation can consequently impact the products formed 
via termination and therefore add to the overall mixture of products formed. Only the 
products formed during termination that do not undergo any further reaction(s) will be 
observed as pyrolytic products [83]. 
2.2.2.1 ELIMINATION REACTIONS 
 
Elimination reactions are very common in pyrolysis and as the name indicates, these 
reactions are characterized by the loss of an atom or atoms. Although it is perceived 
that noticeably smaller products are generated via elimination reactions, radical 
mechanisms in the presence of elevated temperatures have been found to result in 
products that have an increased number of aromatic rings. Two examples of how such 
a mechanism can ultimately lead to ring expansion are illustrated in Figure 19 and 
Figure 20. In these figures, both radical elimination pathways proceed via the same 
steps. The loss (elimination) of a methyl radical from the most substituted carbon atom 
is then followed by an attack on the adjacent benzene atom. In doing so, it provides a 
 
Figure 18: Generalized steps of radical chain reaction mechanisms [82] 
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means for the respective five membered rings to expand to their six membered forms 
[84]. 
 
 
 
 
 
 
 
2.2.2.2 SUBSTITUTION REACTIONS 
 
Substitution reactions are characterized by a replacement or ‘substitution’ of an atom 
or molecular feature and a handful of relevant examples have been included. In each of 
 
 
Figure 19: Example of an elimination reaction leading to heterocyclic ring expansion [84] 
 
 
Figure 20: Example of an elimination reaction leading to homocylcic ring expansion [84] 
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the examples shown, a hydrogen radical is generated and replaced by a larger 
molecular species which leads to the formation of polycyclic species or condensed 
PAH. Figure 21 provides a plausible mechanism by which a bicyclic product is 
generated from benzene molecules. In this representation, the benzene radicals interact 
with one another through radical coupling to produce a product that is larger than the 
initial benzene molecule [83].  
 
 
 
Another example of how a product with a molecular weight greater than the parent 
can be formed is given in Figure 22. Here the relatively small toluene molecules interact 
after the formation of hydrogen radicals and undergo a coupling. In this instance, the 
pathway also shows how the substituted bicyclic product can undergo further 
elimination to yield a fused tricyclic compound that is the PAH phenanthrene [83]. 
 
 
Figure 21: Example of a substitution reaction leading to the formation of a bicyclic 
compound [83] 
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Figure 23 further exemplifies how products of even greater molecular weight can be 
generated. In this pathway, the naphthalene radicals couple together to form a dimer 
complex (binaphthyl species).Similar to the previous figure, this polyclic molecule can 
undergo an elimination to yield yet another well-known PAH, benzo[k]fluoranthene [81]. 
 
 
2.2.2.3 MOLECULAR REARRANGEMENT 
 
The last types of reaction that will be specifically highlighted are molecular 
rearrangement reaction. In this type of reaction, a molecular feature is shifted or 
‘rearranged’ on the structure and therefore results in a structurally similar product. Often 
CH3 CH3
H3C
-H2 -2 H2
H3C
 
Figure 22: Example of a substitution reaction leading to the formation of a polyaromatic 
compound [83] 
 
Figure 23: Example of a substitution reaction leading to the formation of a condensed 
polyaromatic compound [81] 
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times a positional isomer can be formed as a result of molecular rearrangements but 
other types of molecular rearrangements can also occur. 
Listed below, in Figure 24, is an example of how the alkyl substituent of a 
heteroatomic molecule can undergo rearrangement during pyrolysis. This particular 
mechanism is termed a 1,5-sigmatropic rearrangement and is routinely observed with 
the shift of a hydrogen atom. Due to the high temperatures in pyrolysis though, this type 
of rearrangement has also been found to occur with alkyl substituents even larger than 
methyl groups [83]. 
 
 
 
Not all rearrangement reactions produce a positional isomer though, and a separate 
example of a rearrangement reaction that can be observed during pyrolysis is illustrated 
in Figure 25. Driven by the stability of an enlarged aromatic system, this particular type 
of reaction highlights the formation of a more stable PAH species from a conjugation-
rich parent [81]. 
 
 
Figure 24: Example of a molecular rearrangement leading to a positional isomer [83] 
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2.3.0 EXPERIMENTAL 
 
To investigate the formation of various pyrolytic products associated with the 
smoking of synthetic cannabinoids and relevant small molecules of interest, an in-house 
smoking apparatus was used over the course of this study (see Figure 26). The 
apparatus was set up using common laboratory glassware and equipment such that it 
can be performed in many laboratories. 
A plug of quartz wool was placed in the top of a standard five and three-quarter inch 
glass pipette. Depending upon the chemical, between five and ten milligrams of the 
substance was directly weighed onto the plug of wool inside of the glass pipette. 
Another plug of wool was then placed on top of the solid. This quartz wool ‘sandwich’ 
served to hold the chemical in place so that heat could be directly applied to the 
substance. Each chemical substance was analyzed individually with new glass pipettes 
and quartz wool for each trial. 
Once the solid and wool were physically loaded into the pipette, the pipette was 
inserted through a small circular opening in a rubber stopper. The rubber stopper was 
securely fitted into the opening of the Erlenmeyer filter-flask which contained 50 
milliliters (mL) of chloroform. The filter-flask was connected to a vacuum source and the 
 
Figure 25: Example of a rearrangement reaction driven by the stability of aromatic 
systems [80] 
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Figure 26: Diagram of the smoking apparatus used in our experiments 
depth of the glass pipette was adjusted such that when the vacuum was applied, mild 
“bubbling” of the solvent could be observed. Heating of the controlled and non-
controlled substances was carried out using a commercially available handheld 
blowtorch. The torch was held in place with a separate ring stand within a ventilated 
hood so that the distance and orientation of the flame were held constant between runs. 
A more thorough discussion and description of the temperature ranges and length of 
heating will be discussed in the coming sections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chemical 
Quartz Wool 
Glass Pipette 
Rubber Stopper 
Solvent 
  
Connected 
to Vacuum 
Location 
of Torch 
Filter Flask 
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2.3.1 SAMPLE PREPARATION 
 
Using the above apparatus (Figure 26), a total of three separate extracts were 
collected for future analysis: (1) the quartz wool, (2) the interior of the glass pipette, and 
(3) the solvent from the flask. The system was allowed to cool to room temperature 
before the extraction of any constituents. All of the wool was first removed from the 
pipette and placed in a 2 mL plastic syringe to analyze for any remaining solid or 
products that may have been collected. The plastic syringe was fitted with a 0.45 
micrometer (µm) syringe filter and 1 mL of solvent was used to extract the wool directly 
into a 2 mL glass vial. The resulting liquid was then evaporated with air, reconstituted in 
100 microliters (µL) of solvent (90% chloroform: 10% methanol), vortexed for 15 
seconds, and placed into a 200 µL glass insert for GC-MS analysis. All subsequent 
extracts underwent the same preparatory steps (evaporation, reconstitution, and 
transfer). 
The interior of the glass pipette was rinsed with 1 mL of solvent and the resulting 
liquid was directly collected into a 2 mL plastic syringe (also fitted with a 0.45 µm 
syringe filter) for evaluation of the second extract. As for the third fraction, the solvent 
from the bottom of the filter flask was directly evaporated with the previously mentioned 
reconstitution and transfer steps. 
2.3.2 TEMPERATURE MEASUREMENT 
 
In this experimental design, a conventional thermometer would not have been 
suitable for measuring the extreme temperatures occurring during pyrolysis. A 
thermoelectric couple (thermocouple) is ideally suited for such applications and was 
therefore used to monitor the temperature of our experiments. Thermocouples operate 
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on the thermoelectric principle known as the Seebeck Effect. German physicist Thomas 
Seebeck is credited with discovering that when two dissimilar metals (wires) are joined 
at both ends and a temperature difference (T1 and T2) exists between these two ends, a 
voltage is generated [85]. Therefore, by measuring the voltage output with a voltmeter 
(not shown in Figure 27), an accurate temperature reading is provided to the user. 
The point at which the two dissimilar metals are joined is known as a junction point. 
This union of the wires is exposed so it can be directly placed at the site where a 
measurement is needed. The opposite ends of the wires are integrated into an 
isothermal block so that they are held at roughly the same temperature (T2). The metal 
prongs protruding from the isothermal block are plugged into the voltmeter component 
of the device which has various controls as well as a digital display screen for the 
temperature reading. A schematic diagram of the relevant components of a 
thermocouple, like the Omega HH506RA Thermocouple by Omega Engineering, Inc. 
(Stanford, CT) used in this study, is shown in Figure 27 [86]. 
 
 
 
 
Figure 27: Schematic illustrating the primary components of a thermocouple 
 
 
Note: The distance between the two wires has been grossly exaggerated and the length of the 
actual wire has been significantly shortened for display purposes. 
 
 
Ni-Al (- wire) 
Isothermal Block 
Ni-Cr (+ wire) Junction 
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In the above thermocouple schematic, there are two dissimilar metal wires that are 
labeled according to the metals that make up their composition. Many types of metals 
and alloys have been calibrated for use in thermocouples and the variations in metallic 
composition allow these devices to be used in a wide range of applications and over a 
wide range of temperatures. A “Type K” thermocouple which is appropriate for 
measuring temperatures between -200°C and 1250°C was used in the experiments 
described within this work. Such a thermocouple is composed of a nickel-chromium 
alloy for the positive lead and a nickel-aluminum alloy for the negative lead. Above 0°C, 
the limit of error for a Type K thermocouple is the greater of 2.2°C or 0.75%, which was 
deemed sufficient for our purposes [87, 87]. 
2.3.3 HEATING CONDITIONS 
 
Since the intent of this research was to provide useful information about the 
reactions occurring when a synthetic cannabinoid is smoked by an individual, it was 
appropriate to begin by identifying a relevant temperature condition for smoking 
experiments. To simulate the temperature ranges that would be expected with smoking 
plant material laced with synthetic cannabinoids, commercially available cigarettes were 
used to model the heating conditions.  
Marlboro Gold Special Blend (formerly Marlboro Light) cigarettes were used to 
establish the temperature conditions of this study. Two distinctly different thermal 
conditions occur with cigarettes: a “smoldering” condition when the cigarette is lit but not 
actively being smoked and an “inhalation” condition when an individual takes a ‘puff’ 
from the cigarette. To capture the temperature profile of both conditions that can exist, 
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Figure 28: Diagram showing placement of thermocouple in cigarette study 
1 centimeter markings represented with thin blue vertical lines have been added for guidance 
we performed separate replicates with either a low, constant flow through the cigarette 
or with a pulsed, high flow through the cigarette. 
2.3.4 CIGARETTE STUDY 
 
The total length of the cigarettes used was 8 centimeters (cm). The filter portion (tan 
color, Figure 28) of the cigarette measured 3 cm while the remaining 5 cm of the 
cigarette was the actual body (white color) of the cigarette. The thermocouple junction 
was directly inserted through the side of the cigarette at a point that was 1 cm away 
from the lit end of the cigarette. The end of the cigarette that would be put in one’s 
mouth (tan, filter end) was connected to rubber tubing that was attached to a vacuum 
source. A ring stand and clamp were used to hold the cigarette in place within the fume 
hood to avoid exposure to the smoke. In both temperature experiments, the 
thermocouple continuously measured the temperature until the burning front completely 
surpassed the location of the thermocouple wires. 
 
 
  
 
 
 
 
 
In the first part of the investigation of cigarette temperatures, the cigarette was lit and 
the vacuum line was maintained in a slightly opened position such that a minimal 
Location of 
thermocouple 
Air Flow Lit end of the 
cigarette 
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amount of air was continuously drawn from the lit end of the cigarette through the length 
of the cigarette. Again, this scenario was used to experimentally simulate the conditions 
of a cigarette that was not actively being ‘puffed’ by the user (“smoldering”). The 
smoldering temperature was continuously recorded until the burning front of the 
cigarette completely passed the location of the thermocouple. 
For the second portion of the cigarette temperature investigation, a different flow 
was used. Instead of using a constant, minimal flow of air from the vacuum line, the air 
flow was sharply increased as the burning front reached the thermocouple. This sudden 
pulse of air flow was intended to simulate the conditions that would occur during the 
inhalation aspect of smoking a cigarette. 
2.4.0 RESULTS 
 
Thirteen replicates for each smoking condition were conducted with the experimental 
design that was previously discussed in Section 2.3.0. A new cigarette was not 
necessarily used for each replicate unless an insufficient amount of the cigarette 
remained; if more than 3 cm of the body (white color) of the cigarette remained from the 
previous run, then the cigarette was re-used. For example, if after an initial trial, the 
burning front of the cigarette was stopped between 3.0 and 3.5 cm from the start of the 
filter end, then the remaining portion of the cigarette body was used for the following 
trial. 
2.4.1 SMOLDERING CONDITIONS 
 
From the data listed in Table 3, the average minimum temperature of the cigarette, 
which corresponded to the starting temperature of the trial, was found to be between 
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22°C and 29°C (average of 25°C, standard deviation of 2°C). The highest recorded 
temperature for the smoldering scenario was shown to range between 598°C and 
736°C (average temperature of 671°C, standard deviation of 44°C). Overall, the heating 
of the cigarette resulted in an average increase in temperature of 647°C with a standard 
deviation of 44°C. 
In an effort to show how quickly the temperature could elevate in a smoldering 
cigarette, the greatest change in temperature over any 25 second span (ΔT25 sec) of the 
entire trial was calculated (Table 3). Evaluating all trials, it was found that the ΔT25 sec 
varied between 174°C and 391°C, with an average of 288°C and a standard deviation of 
72°C. 
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Table 3: Temperature data for 'smoldering' cigarette conditions 
Replicate 
Minimum 
Temperature 
(°C) 
Maximum 
Temperature 
(°C) 
Overall Change 
in Temperature 
(°C) 
ΔT25 sec (°C) for 
Smoldering 
Scenario 
1 22 736 714 211 
2 25 631 607 174 
3 25 707 682 391 
4 29 629 600 211 
5 23 631 608 266 
6 24 623 599 276 
7 24 689 665 280 
8 23 598 575 317 
9 29 713 685 296 
10 23 665 642 220 
11 26 699 674 345 
12 26 698 672 367 
13 25 707 682 391 
Average 24 671 646 288 
Standard 
Deviation 
2 44 44 72 
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2.4.2 INHALATION CONDITIONS 
 
From the data listed in Table 4, the average and range of temperatures were 
calculated. The initial (minimum) temperature ranged between 21°C and 40°C, with an 
average temperature of 27°C and standard deviation of 5°C. The maximum temperature 
detected by the thermocouple was found to range between 637°C and 762°C, with an 
average of 693°C and a standard deviation of 34°C. Overall, the average increase in 
temperature of the cigarettes was 665°C with a standard deviation of 36°C. The ΔT25 sec 
for the inhalation trials was found to range between 385°C and 706°C with an average 
change of 576°C (standard deviation of 73°C). 
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Table 4: Temperature data for 'inhalation' cigarette conditions 
Replicate 
Minimum 
Temperature 
(°C) 
Maximum 
Temperature 
(°C) 
Overall Change 
in Temperature 
(°C) 
ΔT25 sec (°C) for 
Inhalation 
Scenario 
1 21 682 661 655 
2 21 762 741 683 
3 29 723 694 584 
4 22 707 685 500 
5 25 733 708 706 
6 27 660 633 512 
7 35 660 625 538 
8 25 664 639 495 
9 25 690 665 602 
10 25 637 612 557 
11 30 708 677 623 
12 24 693 669 545 
13 40 681 642 494 
Average 27 692 665 576 
Standard 
Deviation 
6 34 36 73 
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2.5.0 RESULTS AND DISCUSSION FROM CIGARETTE STUDY 
 
Comparing the mean of the two different temperature profiles, one can see that the 
minimum temperature recorded was similar for both scenarios, differing by only 2°C. 
This would be expected, but since not all trials began with an unused cigarette, it was 
important to make note of the starting temperatures so that it can be taken into account 
when evaluating the change in temperature. The average maximum temperature for the 
inhalation condition and average overall change in temperature for the inhalation 
conditions was 21°C and 19°C greater, respectively, than that of the smoldering 
condition. The findings of both the maximum temperature achieved was similar to 
reported temperatures of tobacco [89]. 
There was, however, a significant difference between the ‘greatest change in 
temperature over a 25 second span’ (ΔT25 sec) for the two conditions. The average    
ΔT25 sec observed for the data representing the simulated inhalation scenario (576°C) 
was twice as high as the temperatures observed for the simulated smoldering scenario 
(288°C). These findings helped provide insight into what temperature range these 
studies with synthetic cannabinoids should be conducted at in order to provide data that 
would be as relatable as possible to a real life situation. 
2.6.0 INVESTIGATION INTO PROPER HEAT SOURCE 
 
Once the temperature conditions that occur were experimentally established, an 
adequate heat source for the experimental setup was needed. First and foremost, these 
studies required a heat source that was capable of providing temperatures in excess of 
750°C (coinciding with the maximum temperatures observed in our cigarette studies). 
However, one that was capable of supplying sufficient energy to heat the apparatus at 
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least 550°C in 25 seconds (coinciding with the largest change in temperature observed) 
was most ideal. 
2.6.1 BUTANE HEAT SOURCE 
 
The first type of heat source that was investigated was a common household butane 
lighter (Zippo Multi-Purpose Lighter with premium isobutane fuel; Bradford, PA, USA). 
To evaluate the heating capability of such a lighter, an experimental apparatus with no 
chemical or controlled substance present was set up. The flame from the butane lighter 
was directed at the location where the chemical substance would be located and the 
temperature was measured for a total of 60 seconds. The temperature versus time plot 
of five blank trials are is displayed in Figure 29 while the overall average plot is given in 
Figure 30 . The initial, final, and change in temperature that was observed over the 60 
second run time were extracted from these figures and can be found in Table 5. 
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Figure 29: Temperature profile for butane lighter 
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Figure 30: Average temperature profile for butane lighter 
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Table 5: Temperature ranges observed with butane lighter 
Trial 
Temperature (°C) at 
0 seconds 
Temperature (°C) 
at 60 seconds 
Overall Increase in 
Temperature (°C) over 
60 seconds 
1 21 597 576 
2 22 552 530 
3 22 552 530 
4 22 541 519 
5 22 573 552 
Average 22 563 541 
Standard 
Deviation 
0 22 23 
 
 
 
 
Using the information in Table 5 it was calculated that the average initial, final, and 
overall change in temperature were 22°C, 563°C, and 541°C respectively. Even over 
the course of 60 seconds, the butane lighter did not reach the desired maximum 
temperature of 750°C and was not able to heat the experimental apparatus fast enough 
to match the rapid change in temperature that was observed in the simulated cigarette 
scenarios. Since the temperature capability of the butane lighter did not generate ideal 
output conditions, an alternative heat source that could better match the maximum and 
rate of change observed during the cigarette studies was sought. 
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2.6.2 SUITABILITY OF PROPANE HEATING 
 
Since the majority of lighters use a butane fuel source, a standard handheld propane 
blowtorch (BernzOmatic Propane Torch; Columbus, OH, USA) was investigated for the 
desired heat output. Replicate trials (n=5) were conducted and the ‘blank’ experimental 
apparatus was set up to monitor the temperature capability of the propane torch. Figure 
31 and Figure 32, respectively, provide the individual and average temperature versus 
time plots observed with this particular propane torch. The tabulated results are 
provided in Table 6 for each of the five trials. From this table, it was determined that the 
average starting temperature was 26°C and the average final temperature was 904°C. 
The average overall change in temperature was found to 879°C per minute. 
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Figure 31: Temperature profile for propane torch 
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Figure 32: Average temperature profile for propane torch 
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Table 6: Temperature ranges observed with propane torch 
Trial 
Starting 
Temperature (°C) at 
0 Seconds 
Ending 
Temperature (°C) 
at 60 Seconds 
Overall Increase in 
Temperature (°C) in 60 
Seconds 
1 24 875 851 
2 26 911 885 
3 31 963 923 
4 22 963 940 
5 25 810 785 
Average 26 904 877 
Standard 
Deviation 
3 65 62 
 
 
 
2.6.3 RESULTS AND DISCUSSIONS: HEATING SOURCES INVESTIGATED 
 
In deciding upon an appropriate heat source for these experiments, it is important to 
remember that cigarette temperatures were found to elevate upwards of 700°C in a 25 
second span and approach a maximum temperature of 800°C overall. Using the 
propane torch, the average temperature of the system reached approximately 800°C 
within 20 seconds (see Figure 29) but the butane lighter was unable to surpass 600°C 
in a 60 second time period (see Figure 30). Given the nature by which drugs are 
typically smoked, we sought a heat source that could cause a rapid elevation of 
temperature. After examining the heating profiles, it was determined that the propane 
torch would be more suitable for our particular experimental applications. 
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2.7.0 CONCLUSION 
The temperature profile of a burning cigarette is known to be highly variable and 
difficult to accurately describe. The conditions for the apparatus being used in this study 
were experimentally determined by monitoring the temperature of cigarettes in both a 
smoldering and inhaled state. An increase in temperature of the burning zone by more 
than 500 degrees, with overall temperatures in excess of 700°C, was commonly 
observed with the cigarettes. 
When organic molecules are subjected to such extreme heating conditions, the 
pyrolytic reactions that take place can result in the generation of a number of products. 
While it is expected that pyrolytic products of smaller molecular weight are generated 
via simple bond cleavage, it is not uncommon to find species having a molecular weight 
greater than that of the parent molecule. While the benefits and consequences of 
controlled pyrolysis for industrial and municipal purposes is known, the generation of 
both small and large pyrolytic products through the smoking process can unfortunately 
pose unforeseen health hazards to a given user. 
 
 
 
 
  
57 
 
 
CHAPTER 3: PYROLYSIS OF NON-CONTROLLED SUBSTANCES 
3.1.0 INTRODUCTION 
Given the limited reports regarding the pyrolytic products generated during the 
smoking of synthetic cannabinoids, a comprehensive approach was taken with this 
research. New synthetic cannabinoids are routinely detected by forensic laboratories, 
but the core components which make up the synthetic cannabinoids are not as quick to 
change. Therefore, a select number of chemical moieties that comprise the synthetic 
cannabinoids JWH-018, JWH-030, JWH-081 and UR-144 were experimentally studied 
to better understand the type of pyrolytic products that are likely to form and the 
subsequent health hazards that these compounds may pose. 
As indicated in the previous section, polyaromatic hydrocarbons and heterocyclic 
amines can be formed through various pyrolytic reactions. The toxic and/or carcinogenic 
potential of PAHs and HCAs is a major health-related concern that has been well-
documented by a number of government agencies and international organizations. The 
most common sources of PAH exposure stem from cigarette smoke, automobile 
exhaust, coal processing, and incineration of wastes [74]. As such, individuals are most 
likely to be exposed to a mixture of PAHs (as opposed to a single PAH) and it is 
common to see the health effects of PAHs collectively, rather than individually, 
described. 
The Report on Carcinogens (RoC), provided by the National Toxicological Program 
(NTP), has a number of PAHs, HCAs, and compounds of interest categorized as either 
“known to be human carcinogens” or “reasonably anticipated to be human carcinogens” 
[90, 91].  The Substance Priority List (SPL), which is supplied by the ATSDR and provides 
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information on the most commonly found hazardous chemical substances at sites 
designated by the National Priorities List (NPL), also includes a number of PAHs and 
compounds of interest to this research [75]. For the purpose of this study, the World 
Health Organization (WHO) International Agency for Research on Cancer (IARC) 
monographs on the evaluation of carcinogenic risks to humans were used to classify the 
severity of the pyrolytic products identified [92, 93]. Four distinct carcinogenic categories 
have been established by IARC and the inclusion criteria have been summarized below 
in Table 7. 
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Table 7:  Criteria used by the International Agency for Research on Cancer (IARC) to classify 
carcinogenic pyrolytic products [92] 
IARC 
Carcinogenic 
Classification 
Definition Justification Criteria 
Group 1 Carcinogenic to humans 
 
(a) Sufficient evidence of carcinogenicity 
in humans; OR 
 
(b) Less than sufficient evidence of 
carcinogenicity in humans AND 
sufficient evidence of carcinogenicity 
in experimental animals 
 
Group 2A Probably carcinogenic to humans 
 
(a) Limited evidence of carcinogenicity in 
humans AND sufficient evidence of 
carcinogenicity in experimental 
animals; OR 
 
(b) Inadequate evidence of 
carcinogenicity in humans AND 
sufficient evidence of carcinogenicity 
in experimental animals 
 
Group 2B Possibly carcinogenic to humans 
 
(a) Limited evidence of carcinogenicity in 
humans AND less than sufficient 
evidence of carcinogenicity in 
experimental animals; OR 
 
(b) Inadequate evidence of 
carcinogenicity in humans AND 
sufficient evidence of carcinogenicity 
in experimental animals 
 
Group 3 
Not classifiable as to its 
carcinogenicity to humans 
 
(a) Inadequate evidence of 
carcinogenicity in humans AND 
inadequate or limited evidence of 
carcinogenicity in experimental 
animals 
 
Group 4 
Probably not carcinogenic to 
humans 
 
(a) Evidence suggesting a lack of 
carcinogenicity in humans and 
experimental animals 
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3.2.0 MATERIALS AND METHODS 
The chemicals evaluated for this study were selected because they are smaller 
components that make up the larger molecular structures of JWH-018, JWH-030, JWH-
081, and UR-144. With the exception of 3-naphthoylindole, these non-controlled 
substances have been generically divided into ‘naphthalene-containing compounds’ or 
an ‘indole-containing compounds’ for the purpose of this project. The weight of each 
particular substance that was pyrolyzed can be found in Appendix A. 
3.2.1 NAPHTHALENE-CONTAINING COMPOUNDS 
The naphthalene-containing compounds that were pyrolyzed originated from Sigma-
Aldrich (Saint Louis, Missouri, USA). The four naphthalene-containing compounds 
included in our analysis were: Naphthalene (solid, purity ≥ 99%, CAS No: 91-20-3), 1-
methylnaphthalene (liquid, density of 1.001 g/mL, purity ≥ 95%, CAS No: 90-12-0), 1-
methoxynaphthalene (liquid, density of 1.094 g/mL, purity ≥ 98%, CAS No: 2216-69-5), 
and 1-ethylnaphthalene (liquid, density of 1.008 g/mL, purity ≥ 97%, CAS No: 1127-76-
0). The molecular structures, chemical formula, and molecular weight for these specific 
compounds are provided in Figure 33. 
 
 
 
 
 
Figure 33: The naphthalene-containing compounds investigated in the pyrolysis study 
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3.2.2 INDOLE-CONTAINING COMPOUNDS 
Four indole-containing compounds were also included in this study. Two of these 
compounds originated from Sigma-Aldrich: Indole (solid, purity ≥ 99%, CAS No: 120-72-
9) and 3-methylindole (solid, purity ≥ 98%, CAS No: 83-34-1). Two indole-containing 
compounds were synthesized internally and provided for inclusion in this study: 1-
pentylindole (liquid, purity not provided, CAS No: 59529-21-4) and Indole-3-
carboxaldehyde (solid, purity not provided, CAS No: 487-89-8). The total ion 
chromatogram (TIC) of both in-house synthesized analytes are provided in Appendix 
B. The molecular structure, chemical formula, and molecular weight for each indole-
containing compound is provided in Figure 34. 
 
 
 
3.2.3 3-NAPHTHOYLINDOLE 
The largest non-controlled substance that was included in this study was 3-
naphthoylindole (solid, ≥90%, CAS No: 109555-87-5). This compound, which 
 
Figure 34: The indole-containing compounds investigated in this pyrolysis study 
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represents the core of JWH-018 and JWH-081, was included as an intermediate 
between the smaller naphthalene and indole based components and the much larger 
synthetic cannabinoids. Figure 35 provides the molecular structure, chemical formula, 
and molecular weight of 3-naphthoylindole while Appendix B contains the TIC. 
 
 
3.2.4 INSTRUMENTATION 
Gas chromatography – mass spectrometry (GC-MS) was extensively used 
throughout this research project for analysis of the unknown pyrolytic products. The 
technique couples the separation power of a gas chromatograph with the detection 
capabilities of a mass spectrometer and has long been referred to as the gold standard 
in forensic laboratories. It is also ideal for volatile and semi-volatile substances such as 
drug molecules.  
Ideally, the analytes are individually separated in the gas chromatograph, prior to 
reaching the mass spectrometer, so that the detection is not obscured by simultaneous 
elution of compounds; such was not always achievable in this study. The basic 
components of a gas chromatograph are the carrier gas, injection port, oven, and 
 
 
Figure 35: The dual-containing compound investigated in this pyrolysis study 
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capillary column. When an analyte is injected into the heated GC injection port, the 
sample is simultaneously volatilized and passed onto the column. These volatile and 
semi-volatile analytes are separated as they partition between the mobile phase and 
stationary phase. The mobile phase (carrier gas) is a high purity gas that will not 
chemically interact with the analytes. The stationary phase, located inside of the 
polyimide coated fused silica capillary, provides the partitioning mechanism that 
ultimately separates the analytes as they travel through the length of the column. 
Capillary columns commonly used in forensic analysis are made of polysiloxane with a 
varying degree of phenyl composition (i.e. 1% or 5%). The capillary column is housed in 
a temperature controlled oven that facilitates the separation of the analytes before they 
enter the mass spectrometer. 
The basic components of a mass spectrometer are the vacuum system, ionization 
source, mass analyzer, and detector. The entire MS process is carried out under 
extremely low pressure (~10-8 atmospheres) so that the generation of ions and their 
corresponding flight path can be precisely controlled throughout the mass spectrometer. 
To achieve the low pressure needed, a dual-stage vacuum pumping system (roughing 
pump and turbo molecular pump) is used to create a vacuum within the system. 
After an analyte has been injected into the GC and subsequently eluted from the 
column, it enters the ionization source of the mass spectrometer. A standard electron 
ionization source (70 eV) was used to ionize the gas phase molecules so they could be 
separated based upon their mass-to-charge (m/z) ratio by the mass analyzer.  
A significant amount of fragmentation often occurs in electron ionization because of 
the excess energy absorbed by the parent compound. Therefore, the molecular ion and 
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resulting molecular fragments need to be separated and detected by a mass analyzer 
and detector. A single quadrupole mass analyzer was used in this study and an electron 
multiplier was used to amplify and detect the separated ions as they reached the end of 
the mass spectrometer system. 
Through the use of GC-MS, both a chromatogram and mass spectrum are 
generated and used for the data analysis of a given sample. Coupling retention time 
and the results of the mass spectrum enables analysts to identify a given compound. 
For best practices, a reference standard should be run on the same system to verify 
that the retention time and mass spectrum unequivocally match one another. However, 
if a standard does not exist or cannot be feasibly obtained, analysts often turn to 
commercially available mass spectral databases (“libraries”) for assistance. In such an 
instance, the mass spectrum obtained by a user can be electronically searched against 
a comprehensive spectral library for tentative identification of the analyte. Due to the 
significant number of pyrolytic products being analyzed in this project, commercially 
available mass spectral databases and in-house libraries were heavily relied upon for 
tentative identification when standards were not accessible. 
3.2.5 METHOD PARAMETERS 
All samples were analyzed on an Agilent 7890A gas chromatograph coupled to an 
Agilent 5975C mass spectrometer using a J&W DB-1ms column (30m; 250µm x 
0.25µm). 1.0 µL samples were injected into a 280°C injection port using a 10:1 split 
ratio. Helium at a constant flow of 1 mL/min was used as the carrier gas with a solvent 
delay of 2.20 minutes. The temperature program for the gas chromatograph was initially 
held for 2 minutes at 90°C and then increased 14°C per min to a final temperature of 
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300°C, with a 7 minute hold (34 minute total run time). The transfer line temperature 
was set at 280°C with an ion source temperature of 230°C and quadrupole temperature 
of 150°C. Mass spectra were acquired using a scan range of 30 to 550 atomic mass 
units (amu) with Agilent ChemStation software. 
3.2.6 DATA PROCESSING 
Three individual pyrolysis trials were conducted for each non-controlled substance 
and a condensed version of the data processing steps is illustrated in Figure 36. For 
each of these trials, extracts were collected from the wool, pipette, and solvent layer: 
resulting in a total of nine fractions (i.e. Wool-1, Pipette-1, Solvent Layer-1, Wool-2, 
Pipette-2, etc.) per analyte. Each extract was run in duplicate (Wool-1a, Wool-1b, 
Pipette-1a, etc.) using the GC-MS and method previously described, with solvent blanks 
between injections. The two resulting chromatograms were overlayed using Agilent 
ChemStation software and visually inspected for any discrepancies. 
The analytes that were observed in both replicates, at the same retention time 
(±0.05 min), were further investigated using the instrument software. For a given 
compound, the mass spectrum was searched against the NIST 2014 Mass Spectral 
database and an in-house library for potential matches. A tentative identification was 
made with compounds that, after background subtraction, had a quality score of at least 
70%. 
When a tentative identification could be made for a given analyte it was included in a 
spreadsheet for later analysis. The spreadsheet was used to manage and compare the 
retention time, compound name, and most intense ions observed across the extracts of 
each analyte. Once the data for each chromatogram were input, the list of compounds 
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was further narrowed to include only those that had similar mass spectral profiles and 
library matches. Only the pyrolytic products that appeared in at least two of the three 
extracts for a given compound (i.e. a pyrolytic product identified in two of the three 
pipette extracts for compound ‘X’) were focused on in this report. 
When possible, confirmation of a tentatively identified pyrolytic product was verified 
with a reference standard material and has been noted. Not all the pyrolytic products 
were distinguishable from one another as a result of co-elution and/or low abundance 
levels. Additionally, the mass spectrum of some products did not register a positive 
match in the database being used. Therefore, the results contain only those compounds 
which met the previously mentioned criteria and do not include every observable peak 
found in a particular pyrolytic chromatogram (pyrogram). 
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Figure 36: Condensed schematic of data processing steps 
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3.3.0 RESULTS AND DISCUSSION 
 The pyrolytic products that were reproducibly identified in extracts from each of the 
non-controlled substances analyzed are provided in both tabulated and structure 
formats. The majority of the compounds were tentatively identified (T) but when 
accessible, a reference material was used to verify (V) the identity of a given pyrolytic 
product. Where appropriate, the IARC carcinogenic group that the pyrolytic product 
belongs to (Group 1, 2A, 2B, 3, or 4) is also provided and discussed. Since extracts 
from the quartz wool (W), pipette (P), and solvent (S) were independently analyzed, the 
fraction from which the product was identified is also included. 
3.3.1 MATRIX BLANKS 
Quartz wool (Costech Analytical Technologies, Valencia, California, USA) was 
selected as the substrate for the experimental apparatus due to its relatively inert nature 
and suitability for high temperature conditions. To identify the compounds inherently 
generated as a result of the experimental apparatus being used, matrix blanks were 
performed and extracted using the same previously discussed steps. A pyrogram which 
is representative of the matrix components commonly observed can be found in Figure 
37. 
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Figure 37: Pyrogram representative of the matrix components
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Although tentative identification was not possible for each of the matrix components, 
the retention time was still noted. However, major components that were identified from 
the matrix blanks were as follows: dodecanamide (12.51 min), oleanitrile (13.35 min), 
tetradecanamide (13.77), hexadecanamide (13.91 min), and 9-octadecenamide (15.04 
min). No further investigation of these compounds was pursued and as such these 
particular components were not considered as pyrolytic products when examining the 
pyrograms for the non-controlled and controlled substances. Nearly identical pyrograms 
representative of the wool and solvent layer can be found in Appendix C. 
3.3.2 NAPHTHALENE-CONTAINING COMPOUNDS 
The pyrolysis of the naphthalene-containing compounds resulted in the detection of 
122 total pyrolytic products (see Table 8 and Figure 38). The greatest number of 
identifiable products were observed with 1-methoxynaphthalene (73), followed by 1-
ethylnaphthalene (63), naphthalene (38), and 1-methylnaphthalene (36). Overall, the 
majority of the pyrolytic products observed were substituted and unsubstituted PAHs. 
Nine products were observed in at least one extract from each of the four of the 
analytes pyrolyzed: naphthalene, 1-methylnaphthalene, 2-methylnaphthalene, 2-
ethenylnaphthalene, biphenyl, anthracene, 9-(phenylmethylene)-9H-fluorene, 1,2’-
binaphthalene, and 2,2’-binaphthalene. These were, therefore, considered to be non-
specific. 
While three, four, and five membered ring systems were identified as products 
across all the naphthalene-containing compounds, it was also found that certain 
pyrolytic products were only observed in the extracts of certain analytes. Sixty-five of 
the 122 pyrolytic products (53%) were only identified in extracts from one of the four 
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analytes, compared to the nine previously mention compounds were identified in 
extracts from all analytes. Figure 39 shows the distribution of the 122 identified pyrolytic 
products among the four analytes pyrolyzed and provides insight into the ‘uniqueness’ 
of the pyrolytic products.  
As mentioned previously, it is not uncommon for PAHs to be collectively categorized 
with a given health-hazard. However, seventeen of the chemicals that were identified as 
a result of the pyrolysis of these naphthalene-containing compounds have been 
individually listed by the IARC. Six of these compounds were identified in at least three 
of the four analytes studied: the Group 2B carcinogens naphthalene, benzo[k]fluorene, 
and benz[a]anthracene, as well as the Group 3 carcinogens anthracene, fluoranthene, 
perylene. The other eleven compounds were identified in one or two of the analytes: 
Group 2B carcinogens – styrene, benzofuran, benzo[c]phenanthrene; Group 3 
carcinogens – phenol, coumarin, acenaphthene, fluorene, phenanthrene, pyrene, 11H-
benzo[b]fluorene, and dibenz[a,h]anthracene. 
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Table 8: Pyrolytic products identified from investigation of the naphthalene-containing 
compounds 
Retention 
Time (min) 
Compound ID CG Naphth. 
1-CH3 
Naphth. 
1-OCH3 
Naphth. 
1-C2H5 
Naphth. 
2.68 Phenylacetylene T - P    
2.82 Styrene T 2B P    
3.29 Benzaldehyde T - P    
3.41 Phenol T 3 P    
3.75 Benzofuran T 2B P    
4.20 3-Methylphenol T - P    
4.27 Indene T - P P P  
5.44 2-Methylindene T - P  P  
5.48 Azulene T -  P P, S  
5.78 Naphthalene V 2B P P P, S P 
5.96 2,3-Dimethylindene T -   P  
6.27 Quinoline V - P P S  
6.53 2-Ethylindene T -   P  
6.58 1-Methylindole V -   S  
6.62 1-Indone T - P    
6.67 Benzocylcoheptatriene T -   P, S  
6.73 Indole T -  P P  
6.82 Phthalic anhydride T -   S  
6.99 1-Methylnaphthalene V - P P P P 
7.02 2-Methylquinoline T -  S   
7.14 2-Methylnaphthalene T - P S P W, P, S 
7.20 3-Phenylfuran T -   S  
7.24 1-Ethylidene-indene T -   P  
7.47 3-Methylquinoline V -   P  
7.62 3,4-Dihydro-1(2H)-naphthalenone T -    P 
7.71 2-Methylindole V - P    
7.82 Coumarin T 3 P  P  
7.88 1,4-Naphthalendione T - P  S  
7.99 1-Ethylnaphthalene V -  P, S P W, P, S 
8.12 2-Ethenylnaphthalene T - P P P W, P, S 
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8.23 2,3-Dimethylnaphthalene T -  P P P 
8.29 Biphenyl T - P P P W, P 
8.38 1-Methoxynaphthalene V -  S W, P, S W, S 
8.43 1,4-Dimethylnaphthalene T -  P  P 
8.45 Acenaphthylene T - P P  W, P, S 
8.54 1,2-Dimethylnaphthelene T -  P P P 
8.58 2-(1-Methylethyl)naphthalene T -    P 
8.61 1-(1-Methylethyl)naphthalene T -    P 
8.80 Acenaphthene V 3  P  W, P, S 
8.84 1-Naphthalenecarboxaldehyde T -  P   
8.86 1-Naphthalenol T - P  P, S S 
8.95 2-Naphthalenol T - P   P 
8.99 2,4-Di-t-butylphenol T -   W W, P 
9.00 Menadione T -   P, S  
9.11 1-Isopropenylnaphthalene T -    P 
9.14 1,4,6-Trimethylnaphthalene T -    P 
9.16 
4-Hydroxy-4-methyl-naphthalen-
1-one 
T -   P, S P 
9.29 1(2H)-Acenaphthylenone T - P  P, S  
9.43 4-Methyl-1,1’-biphenyl T -    P 
9.47 1-Naphthalenemethanol T -  P, S  S 
9.52 1-(1-Naphthalenyl)-ethanone T -    W, S 
9.54 6-Phenyl-3,5-hexadien-2-one T -   P, S  
9.63 1H-Phenalene T -    P 
9.69 Fluorene V 3 P   P 
9.74 α-Methyl-2-naphthalenemethanol T -    W, P, S 
9.78 1-(2-Propenyl)naphthalene T -   P P 
9.89 1-Dimethoxymethylnaphthalene T -  P, S P W, P, S 
9.93 
2-Naphthalenecarboxylic acid 
methyl ester 
T -    S 
9.98 2-Methyl-1-naphthalenol T -   P  
10.19 Dibenzofuran T -   S P, S 
10.21 1-Acenaphthenol T -    P 
10.30 [1,1’-Biphenyl]-4-carboxaldehyde T -   P, S  
10.34 1-Methyl-9H-fluorene T -    P 
10.40 2-Hydroxyfluorene T -   P, S  
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10.44 5,7-Dimethyl-1-naphthol T -   P, S  
10.56 3-Hydroxybiphenyl T -   S  
10.61 2-Ethyl-3-methylene-indan-1-one T -   P, S  
10.71 [1,1’-Biphenyl]-2,5-diol T -   S  
10.85 
N,N-Dimethyl-1-
naphthaleneamine 
T -    P 
10.86 9H-Fluoren-9-one T -   P, S  
10.93 
2-Hydroxy-1-naphthoic acid 
methyl ester 
T -   S  
11.06 1-[1,1'-Biphenyl]-4-yl-ethanone T -   P, S  
11.26 Anthrancene V 3 P, S P P, S P, S 
11.36 Phenanthrene T 3 P   P 
11.51 1-(1-Naphthyl)-1,2-ethanediol T -   S  
11.56 Anthrone T -   S  
11.83 1-(Phenylmethylene)indene T - P P P, S  
11.87 2-Phenyl-1H-indene T -   S  
12.03 1H-Phenalen-1-one V -   S P, S 
12.05 4-Hydroxy-1-naphthaldehyde T -   S  
12.10 
1H,3H-Naphtho[1,8-cd]pyran-1-
one 
T -    P 
12.30 4H-Cyclopenta[def]phenanthrene T -    S 
12.32 1-Methylanthracene T -   S  
12.64 1-Phenylnaphthalene T - P  P, S  
12.88 Naphthalic anhydride T -    P, S 
13.05 6,6-Diphenylfulvene T - P    
13.20 
8-Formyl-1-naphthalenecarboxylic 
acid 
T -    S 
13.30 Fluoranthene V 3 P  P, S P, S 
13.44 2-Styrylnaphthalene T - P    
13.61 9-Phenanthrol T -   S  
13.64 Pyrene T -   S P, S 
13.71 Benzo[b]naptho[2,3-d]furan T - P  S  
13.80 p-Terphenyl T -   S  
13.99 1-Phenyl-2-naphthalenol T -   S  
14.26 11H-Benzo[b]fluorene T -   P, S  
14.39 7H-Benzo[c]fluorene T - P  P, S  
15.07 9-(Phenylmethylene)-9H-fluorene T - P, S S S P, S 
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15.35 Benzo[c]phenanthrene T 2B P  P, S  
15.42 11H-Benzo[a]fluorene-11-one T -   S  
15.53 9-Phenyl-9H-fluorene T -   S  
15.69 Benz[a]anthrancene V 2B P  P, S P 
15.75 Naphthacene T - S  P, S P 
15.81 1,2'-Binaphthalene T - P P, S P, S P, S 
15.96 3-Methylcholanthrene T -  S  P, S 
16.40 
1-(2-Naphthalenylmethyl) 
naphthalene 
T -  P, S  P, S 
16.46 
9,10-Dihydro-8-
methylbenzo[a]pyrene 
T -  P, S  P, S 
16.51 1,1’-Methylenebis-naphthalene T -    P, S 
16.55 7-Methyl-benz[a]anthracene T -   S  
16.61 2-Methylcholanthrene T -  P, S  P, S 
16.66 2,2'-Binaphthalene T - P, S P, S P, S P, S 
16.75 1,1'-Binaphthalene T -  P, S P, S S 
17.15 3,3’-Dimethyl-1,1’-binaphthalene T -  P, S  P, S 
17.23 8,8’-Dimethyl-1,1’-binaphthalene T -  P, S  S 
17.33 1-Phenylpyrene T -    P, S 
17.37 4,4’-Dimethyl-1,1’-binaphthalene T -  S  S 
17.46 Benzo[k]fluoranthene T 2B  S P, S P, S 
17.54 Dinaphtho[1,2-b:1',2'-d]furan T -   P, S  
17.91 Benzo(a)pyren-7-ol T -   P, S  
18.01 2,2-Dimethyl-1,1’-binaphthalene T -  P, S  S 
18.10 Perylene V 3  P, S S P 
18.48 2,3-Diphenyl-inden-1-one T -   P, S P, S 
19.99 Dibenz[a,h]anthracene T 3   P, S P, S 
Identification (ID) refers to whether the pyrolytic product was tentatively identified, T, or verified with a 
reference material, V. The carcinogenic group (CG) indicates the IARC classification to which the analyte 
belongs [1, 2A, 2B, 3, or 4]. The extract in which the pyrolytic product is indicated with a single capital 
letter representative of each of the three extracts: W (wool), P (pipette), and S (solvent layer). 
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Figure 38: Pyrolytic products identified from naphthalene-containing analytes 
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Figure 39: Inter-comparison of pyrolytic products between naphthalene-containing 
compounds 
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3.3.3 INDOLE-CONTAINING COMPOUNDS 
A total of 111 pyrolytic products were identified from the four indole-containing 
compounds that were studied (Table 9 and Figure 40). As would be expected, there 
were significantly more nitrogen-containing pyrolytic products; the majority of which 
were bridged or fused HCAs. Similar to the naphthalene containing compounds, an 
overwhelming number of products are of greater molecular weight than that of the 
indole-containing compounds themselves (117, 131, 145, and 187 amu). The greatest 
number of identifiable pyrolytic products was observed with 3-methylindole (59); 
followed by indole (44), indole-3-carboxaldehyde (36), and 1-pentylindole (26). 
Figure 41 provides the distribution of the 111 pyrolytic products among the extracts 
of the four analytes and shows that two-thirds (66%) of the pyrolytic products were 
identified in only one of the indole-containing compounds. Four pyrolytic products were 
observed in extracts from each of the four analytes: indole, quinoline, 
benzo(h)quinoline, carbazole, and 9-anthracenececarbonitrile. An additional six 
products were observed in extracts from three of the four analytes: benzyl nitrile 
(phenyl-acetonitrile) naphthalene, oxindole, naphthalene-2-carbonitrile, and indole-5-
carboxaldehye. 
Seventy-three of the total compounds (66%) were only identifiable in an extract from 
one of the four indole-containing analytes. Four of the pyrolytic products observed are 
categorized as carcinogens. 2-Naphthylamine is classified by the IARC as known 
human carcinogen (Group 1). Naphthalene, identified in extracts of three of the four 
analytes, and carbazole, identified in extracts from all analytes are both Group 2B 
carcinogens. Fluorene, only identified in the indole extract, is listed in Group 3. 
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Table 9: Pyrolytic products identified from investigation of the indole-containing compounds 
Retention 
Time 
(min) 
Compound ID CG Indole 
3-CH3 
Indole 
1-pentyl 
Indole 
Indole-
3-
Carbox. 
3.44 Benzonitrile T - P S   
4.35 4-Methylbenzonitrile T - P S   
4.41 o-Aminotoluene V - P    
4.95 Benzyl nitrile T - P P  P 
5.07 2-Hydroxybenzonitrile T -    P 
5.37 Benzoic acid T -  P   
5.47 4-Aminostyrene T -  P   
5.54 3-Phenyl-2-propenenitrile T -  P, S  P 
5.76 Naphthalene V 2B P P  P 
6.14 α-Methylene benzeneacetonitrile T -  P   
6.27 Quinoline V - P P S P, S 
6.50 Isoquinoline T -  P S  
6.58 1-Methylindole V -  P   
6.73 Indole V - W, P, S P, S P*, S* W, P, S 
6.82 1-(2-Aminophenyl)ethanone T -  
W, P, 
S 
  
7.01 2-Methylquinoline V -  P, S S  
7.27 3-Acetylbenzonitrile T -  P   
7.28 Methyl anthranilate T -  S  P 
7.48 1-Acetylisatin T - S    
7.60 2(1H)-Quinolinone T -    W, P, S 
7.62 1,3-Dimethylindole T -  P   
7.66 2-Methylindole V -  P, S P, S  
7.68 3-Methylindole V -  W  P, S 
7.88 
2-Methyl-4H-3,1-benzoxazin-4-
one 
T -  P, S   
7.98 1-Ethylnaphthalene V -  S   
8.16 1,2-Dimethylindole T -  P   
8.22 (Phenylmethylene)propanedinitrile T - P P   
8.34 2,4-Dimethylquinoline T -   S  
8.37 Oxindole V - P P, S  P, S 
8.39 1-Methoxynaphthalene V -   P, S P 
8.45 2,6-Dimethylindole T -  P   
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8.54 2,6-Dimethylphenyl isocyanate T -  W, S   
8.55 1-Ethylindole T -  P P, S  
8.60 Indole-7-carboxaldehyde T -   S S 
8.61 Indole-3-carbonitrile T - P   P 
8.63 2,4,6-Trimethylbenzonitrile T -  P   
8.64 1,4-Dimethylindole T -  P   
8.71 2,3-Dimethylindole T -  P P  
8.72 Naphthalene-1-carbonitrile T -   P  
8.75 Quinoline-3-carbonitrile T - P P   
8.79 Indole-3-acetaldehyde T -  P, S   
8.87 1-Naphthalenol T -   S  
8.88 (2-Acetylphenyl)formamide T -  
W, P, 
S 
  
8.96 Naphthalene-2-carbonitrile V - P P P  
8.98 2,4-Di-t-butylphenol T -  W, P   
9.01 2,5-Dimethylindole T -  P   
9.11 Quinoline-2-carbonitrile T - P P   
9.12 2-Ethyl-4-methyl-quinoline T -  P   
9.24 2-Naphthylamine V 1  P P, S  
9.27 N-(2-Acetylphenyl)acetamide T -  P, S   
9.31 4-Methyl-2(1H)-quinolinone T -   S  
9.33 4-Hydroxyindole T - P    
9.37 3-Propylquinoline T -   S, P  
9.43 5-Hydroxyindole T - P    
9.44 Indole-5-carbonitrile T -  P  P 
9.45 1-Propylindole T -   P  
9.46 2,6-Dicyanotoluene T - P    
9.69 Fluorene V 3 P    
9.85 7-Methyl-8-quinolinol T -  S W, S  
9.87 1-Pentylindole V -   W, P, S  
10.07 
1-(2'-Methylaminophenyl)-1-
pentanone 
T -   P, S  
10.17 Isatin V -  P  W, P, S 
10.33 6-(1-Methylpropyl)quinoline T -   P  
10.57 1,3-Diacetylindole T -   S*  
10.63 4-(3-Methylbutyl)-1H-indole T -   P, S  
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10.69 1-Pentyl-3-methylindole T -   P*, S*  
11.00 
3,5-Dimethyl-2-phenylpiperidin-4-
one 
T -   P*, S*  
11.03 Indole-3-acetonitrile T -  P   
11.06 Indole-3-carboxaldehyde V - P, S   W, S 
11.07 Indole-5-carboxaldehyde T -  S S P 
11.29 Benzo(h)quinoline T - P P S P 
11.48 
Indole-3-carboxylic acid methyl 
ester 
T -    W, P, S 
11.53 Carbazole T 2B P P P, S P* 
11.61 2-Methyl-indole-3-carboxaldehyde T -  P, S   
11.70 1-Methyl-3-acetylindole T -  P, S   
11.88 9H-Fluorene-2-carbonitrile T -  P   
12.04 Iminostilbene T - P    
12.15 3-Methylcarbazole T -   S  
12.22 6-Phenylisoquinoline T - P P   
12.29 4H-Benzo[def]carbazole T - P P   
12.35 2-Methylcarbazole T -   P, S  
12.47 9-Methylcarbazole T -   P, S  
12.85 2-Phenylquinoline T - P P   
12.87 1-Anthracenamine T - P    
12.95 4-Phenylisoquinoline T - P P   
13.10 2-Phenylindole T - P P   
13.24 3-Phenylindole T - P  P  
13.27 Acenaphtho(1,2-b)pyridine T -    P 
13.32 2-Methyl-benzo[f]quinoline T - P    
13.38 Indeno(1,2,3-ij)isoquinoline T - P    
13.43 9-Anthracenecarbonitrile T - P P  P 
13.46 9-(Cyanomethylene)fluorene T - P    
13.62 [1,1'-Biphenyl]-2,2'-dicarbonitrile T - P    
14.59 Benzo(a)phenazine T - P    
14.82 9-(Dicyanomethylene)fluorene T - P    
14.83 7H-Benzo(c)carbazole T - P    
15.17 4,4'-Dimethoxydiphenylamine T -   S  
15.55 2-(3-Isoquinolinyl)benzonitrile T -    P 
15.62 
4H-Benzo[e]pyrido[1,2-
a]benzimidazole 
T - P   P 
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15.66 11H-Benzo[a]carbazole T -   S  
15.75 Benzo(b)phenazine T - P, S   P 
15.79 Dibenzo[c,h][2,6]naphthyridine T -    S 
15.93 Benzo(b)carbazole T -   P  
16.11 Benzo[b]naphtho[2,3-d]furan T -  P   
16.13 1H-Phenanthro[9,10-c]pyrazole T - P    
16.22 1H-Phenanthro[9,10-d]imidazole T - P    
16.36 
2-Methyl-1H-indeno[1,2-
b]quinoxaline 
T - P    
16.91 7-Methyl benz[a]anthracene T -   P  
17.23 
1-(1H-Inden-2-yl)-1H-
benzimidazole  
T - P    
17.43 
2-Phenyl-5H-imidazo(2,1-
a)isoindole  
T - P    
20.03 6,6'-Biquinoline T -  P   
20.75 2,2'-Biquinoline T -  P   
Identification (ID) refers to whether the pyrolytic product was tentatively identified, T, or verified with a 
reference material, V. The carcinogenic group (CG) indicates the IARC classification to which the analyte 
belongs [1, 2A, 2B, 3, or 4]. The extract in which the pyrolytic product is indicated with a single capital 
letter representative of each of the three extracts: W (wool), P (pipette), and S (solvent layer). 
 
*Observed as impurities in the analytical standard that was pyrolyzed and therefore may not be a true 
pyrolytic product 
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Figure 40: Pyrolytic products identified from indole-containing analytes 
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Figure 40 continued 
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Figure 40 continued 
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 Figure 40 continued 
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Figure 40 continued 
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Figure 41: Inter-comparison of pyrolytic products between indole-containing compounds 
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3.3.4 3-NAPHTHOYLINDOLE 
Fifty-nine total products were identified from the pyrolysis of 3-naphthoylindole 
(Table 10 and Figure 42). Numerous pyrolytic products that were identified with 3-
naphthoylindole were also observed with the naphthalene and indole-containing 
analytes; including naphthalene and indole themselves. No pyrolytic products were 
identified in the wool extract and none of the products were solely identified in solvent 
layer extract.  
Thirty-six products were identified in only the pipette layer, with the remaining 
twenty-three compounds being identified in both the pipette and solvent layer. Twenty 
pyrolytic products identified from 3-naphthoylindole were not observed with the pyrolysis 
of the other analytes. Among these compounds were 4-membered ring systems, such 
as chrysene, two naphtho-quinoline species, and amino-substituted pyrene, chrysene, 
and benzo(c)phenanthrene.  
Ten products identified are specifically classified as carcinogens according to IARC. 
The Group 2B carcinogens 11H-Benzo[b]fluorene and carbazole and the Group 3 
carcinogens phenol, acenaphthene, fluorene, and 7H-benzo[c]fluorene were only 
identified in the pipette layer. The Group 2B carcinogens naphthalene and chrysene, 
and the Group 3 carcinogens anthracene and fluoranthene, were identified in both the 
solvent layer and pipette extracts. 
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Table 10: Pyrolytic products identified from investigation of 3-naphthoylindole 
Retention 
Time (min) 
Compound ID CG 
 
Naphthoylindole 
3.30 Benzaldehyde T - P 
3.41 Phenol T 3 P 
4.20 3-Methylphenol T - P 
4.26 Indene T - P 
4.34 4-Methylbenzonitrile T - P 
4.41 o-Aminotoluene T - P 
4.94 Benzyl nitrile T - P 
5.67 1,2-Naphthalenedione T - P, S 
5.80 Naphthalene V 2B P, S 
6.25 Quinoline V - P, S 
6.73 Indole V - P, S 
7.13 2-Methylnaphthalene T - P 
7.69 2-Methylindole V - P 
7.87 1,4-Naphthalendione T - P, S 
8.10 2-Ethenylnaphthalene T - P 
8.34 Oxindole V - P, S 
8.46 Acenaphthylene T - P, S 
8.72 Naphthalene-1-carbonitrile T - P, S 
8.80 Acenaphthene V 3 P 
8.88 1-Naphthalenol T - P, S 
8.93 2-Naphthalenol T - P, S 
8.99 2,4-Di-t-butylphenol T - P 
9.67 Fluorene V 3 P 
9.85 2H-Naphtho[1,8-bc]furan-2-one T - P, S 
10.18 Dibenzofuran T - P 
10.28 N-Methyl-2-naphthamide T - P 
10.33 1-Naphthalenecarboxylic acid T - P 
10.86 9H-Fluoren-9-one T - P 
11.05 Indole-3-carbonitrile T - P 
11.26 Anthracene V 3 P, S 
11.54 Carbazole T 2B P 
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11.83 1-(Phenylmethylene)indene T - P, S 
12.02 Iminostilbene T - P 
12.64 1-Phenylnaphthalene T - P 
12.85 1-Anthraceneamine T - P 
13.09 2-Phenylindole T - P 
13.30 Fluoranthene V 3 P, S 
13.71 Benzo[b]naptho[2,3-d]furan T - P 
14.27 11H-Benzo[b]fluorene T 2B P 
14.39 7H-Benzo[c]fluorene T 3 P 
14.57 Chrysene T 3 P, S 
14.63 5,6-Dihydrochrysene T - P, S 
15.04 9-(Phenylmethylene)-9H-fluorene T - P, S 
15.40 Benz[c]acridine T - P 
15.64 Naphtho(2,3-h)quinoline T - P 
15.67 11H-Benzo[a]carbazole T - P, S 
15.75 Naphthacene T - P 
15.81 1,2'-Binaphthalene T - P, S 
15.90 7H-Benz[de]anthracen-7-one T - P 
15.95 Naphtho(2,1-f)quinoline T - P 
16.02 1-Aminopyrene T - P 
16.11 N-(1-Naphthoyl)-sarcosine ethyl ester T - P, S 
16.21 Benzo(c)phenanthren-2-amine T - P 
16.54 Dibenzo(b,def)carbazole T - P, S 
16.73 6-Chrysenamine T - P 
17.03 Benzo(c)phenanthren-3-amine T - P 
17.13 Benzo(c)phenanthren-5-amine T - P, S 
17.97 12,13-Dihydro-7H-dibenzo(a,g)carbazole T - P 
18.90 3-Naphthoylindole V - P, S 
Identification (ID) refers to whether the pyrolytic product was tentatively identified, T, or verified with a 
reference material, V. The carcinogenic group (CG) indicates the IARC classification to which the analyte 
belongs [1, 2A, 2B, 3, or 4]. The extract in which the pyrolytic product is indicated with a single capital 
letter representative of each of the three extracts: W (wool), P (pipette), and S (solvent layer). 
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Figure 42: Pyrolytic products identified with 3-naphthoylindole 
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Figure 42 continued 
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Figure 42 continued 
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Figure 42 continued 
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3.4.0 CONCLUSION 
Given that several classes of synthetic cannabinoids are based upon the same 
molecular core and similar moieties, it is important to understand the pyrolytic fate of 
such chemicals. The nine compounds included in this study were purposefully selected 
as they represent smaller components of each of the four synthetic cannabinoids of 
interest: JWH-018, JWH-030, JWH-018, and UR-144. By experimentally identifying the 
products that are formed during the pyrolysis of these smaller components, insight 
regarding the possibility of generating certain chemicals during the process of smoking 
synthetic cannabinoids has been provided. 
Twenty-one products that were identified are specifically classified as carcinogenic 
species by the International Agency on Research for Cancer. With synthetic 
cannabinoids consisting of these very same chemical components that generate 
carcinogenic or potentially carcinogenic pyrolytic products, there is reason for concern 
regarding the chronic use of such designer drugs.  
Not all the pyrolytic products that were identified have been assessed by the NTP or 
IARC. The health effects of chronic exposure to a multitude of the pyrolytic products 
identified should therefore not be overlooked. For instance, although not listed as 
carcinogens by IARC, the U.S. EPA Integrated Risk Information System Database 
states there is “suggestive evidence of carcinogenic potential” associated with exposure 
to biphenyl, with aniline, 3-methylphenol, and quinoline listed as a “probable 
carcinogens” [94]. Likewise, 3-methylcholanthrene, which was identified in two of the 
naphthalene-containing compounds, is listed as a Category 1B carcinogen according 
the Globally Harmonised System of Classification and Labelling of Chemicals (GHS). 
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The results of this study indicate that a number of concerning PAHs and HCAs can 
be generated as pyrolytic products of the molecular moieties that make up specific 
synthetic cannabinoids. This does not necessarily imply that these compounds will be 
created with the synthetic cannabinoids themselves, but rather serves to provide insight 
into compounds that may be formed. In the following chapter, the results of the pyrolysis 
of the synthetic cannabinoids will be discussed and compared to the smaller 
components investigated in this chapter. 
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CHAPTER 4: PYROLYSIS OF SYNTHETIC CANNABINOIDS 
4.1.0 INTRODUCTION 
Since initially being identified in the U.S. in December 2008, synthetic cannabinoids 
have become one of the largest and most challenging forensic-related drug problems. 
Domestically, NFLIS indicated that 19,838 drug reports were analyzed between January 
2014 and June 2014 involving synthetic cannabinoids [95]. In the European Union, there 
were 101 previously unreported NPS that were identified in the year 2014 alone; thirty 
of which were synthetic cannabinoids [96]. With the rapid and continuous influx of new 
compounds, forensic laboratories have struggled to prevent backlogs from rising. As 
such, much of the current body of research regarding synthetic cannabinoids has been 
primarily focused on the development of new methodology to detect the parent drug 
and/or the primary metabolites. 
The lack of scientific articles discussing the toxicity and pharmacology of synthetic 
cannabinoids is in part hindered by the unavailability of reports detailing what are the 
pyrolytic products of synthetic cannabinoids. The specific focus of this study was to 
thoroughly evaluate the products that are generated upon pyrolysis of the synthetic 
cannabinoids JWH-018, JHW-030, JWH-081, and UR-144. These particular compounds 
were selected in part due to their prevalence in the beginning generations of synthetic 
cannabinoids, but more importantly because of the structural similarity to one another. 
Exhaustive efforts were taken to identify all pyrolytic products for these four compounds 
with the intent to provide a foundation for which future studies can build upon. 
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4.2.0 MATERIALS AND METHODS 
JWH-018 (solid, purity ≥98.5%, CAS No: 209414-07-3), JWH-081 (solid, purity 
≥99%, CAS No: 210179-46-7), and UR-144 (solid, purity ≥ 99%, CAS No: 1199943-44-
6) were provided by the DEA Reference Materials Program. JWH-030 (20mg/mL 
dissolved in methanol, purity ≥98%, CAS No: 162934-73-8) was purchased from 
Cayman Chemicals (Ann Arbor, Michigan, USA). The molecular structures of these 
controlled substances can be found in Figures 13 and 15, respectively. The amount of 
synthetic cannabinoid that was pyrolyzed in each trial can be found in Appendix D. 
4.2.1 EXPERIMENTAL 
The pyrolyzed extracts obtained from each of the individual synthetic cannabinoids 
were analyzed using the same sample preparation, instrument conditions, and method 
parameters as previously discussed with the non-controlled substances. See Section 
3.2.0 for reference. The same data processing steps were also taken for all pyrolytic 
products listed in the data tables. Representative pyrograms of the wool, pipette, and 
solvent layer extracts for JWH-030, JWH-018, JWH-081, and UR-144 have been 
provided in Appendix E, Appendix G, Appendix I, and Appendix K, respectively. 
4.3.0 RESULTS AND DISCUSSION 
Given the unique structures of synthetic cannabinoids, it was anticipated that not all 
pyrolytic products would register with the commercially available NIST 2014 spectral 
database. To avoid elimination of potentially valuable compounds for pyrolytic products 
that were reproducibly observed and showed fragmentation patterns consistent with 
those known of synthetic cannabinoids, quality score was neglected. Any compound 
that was included as a result of the broadened criteria has been omitted from the data 
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tables and is instead discussed within the text of each respective section with an 
emphasis placed on proposing possible structures.  
4.3.1 PYROLYSIS OF JWH-030 
Nineteen pyrolytic products were identified with JWH-030. Reference standards 
were available to verify four of the reported products (see Table 11 and Figure 43), 
while the other species were tentatively identified. Possessing a naphthoyl-pyrrole core, 
it was expected that the pyrolytic products of JWH-030 would correlate with products 
identified from the naphthalene-containing compounds rather than those from the 
indole-containing compounds. Eleven of the nineteen JWH-030 products were observed 
with the naphthalene-containing compounds: naphthalene, 1,4-naphthalenedione, 
acenaphthylene, 1-naphthalenecarboxaldeyde, 1-naphthalenol, 2-naphthalenol, 1-(1-
naphthalenyl)naphthalene, 1-dimethoxynaphthalene,  2-naphthalenecarboxlyic acid 
methyl ester, anthracene, and 1H-phenalen-1-one. Both naphthalene and anthracene 
are listed as Group 2B and Group 3 IARC carcinogens and as such, exposure to these 
compounds should be considered when evaluating the long-term health effects of 
smoking JWH-030. 
Despite not possessing an indole or naphthoyl-indole core, there were some JWH-
030 pyrolytic products that were observed with the 3-naphthoylindole and indole-
compounds from the previous chapter. Both naphthalene and 1-naphthalenol, which 
were identified in many of the non-controlled substances, were identified as a result of 
the pyrolysis of JWH-030. 2H-naphtho[1,8-bc]furan-2-one and 1-naphthalenecarboxylic 
acid were also tentatively identified with JWH-030. Although these compounds may not 
necessarily be unique to 3-naphthoylindole, they were exclusive to 3-naphthoylindole in 
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the context of this study. The identification of the two products suggests that only the 
naphthoyl-pyrrole functionality, not the entire indole counterpart, is necessary to 
generate them during pyrolysis. A naphthoyl-pyrrole standard analogous to that of 3-
naphthoylindole was unavailable for pyrolytic investigation to help resolve this issue. 
Excluding the parent molecule, there were five pyrolytic products identified in the 
JWH-030 extracts that were not identified with the non-controlled substances: 2-
naphthalenecarboxylic acid, 1-naphthamide, 2-phenylindole-3-carboxaldehyde, N-
pentyl-2-naphthamide, and (4H)-thebenidinone. Reference materials were not available 
to verify whether these compounds could potentially be suitable pyromarkers. It is worth 
noting that the compound tentatively identified at 13.96 minutes as 2-phenylindole-3-
carboxaldehyde has the same chemical formula (C15H11NO; MW =221.26) as that of 3-
(1-naphthoyl)pyrrole but without a reference material this too was unable to be identified 
in this study. 
There were five pyrolytic products consistently observed with appreciable 
abundance in the pyrograms that were unable to be identified. The m/z 127 and 155 
ions, which correspond to the naphthalene and naphthoyl fragments, are routinely 
observed with the naphthoyl-indole and naphthoyl-pyrrole classes of synthetic 
cannabinoids. The mass spectrum of the unknown pyrolytic products at 13.15, 13.25, 
13.90, 17.23, and 17.51 minutes are provided in Appendix F.  
The unknowns at 13.15 and 13.25 minutes have nearly identical mass spectra, 
suggesting that they are isomeric variations of the same compound. In this particular 
case, the complexity of the spectra, or possible co-elution with another analyte, 
prevented a possible structure and/or explanation of the fragmentation pathway from 
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being reported; except the presumed likelihood that the compound contains a 
naphthoyl-entity. The two unknowns at 13.90 and 17.23 minutes had minimal 
fragmentation that could be used for structural elucidation, while the unidentified 
compound at 17.51 minutes was uninterpretable. No decision can be made at this time 
regarding the potential of these compounds as specific pyromarkers for JWH-030. 
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Table 11: Pyrolytic products identified from investigation of JWH-030 
Retention 
Time (min) 
Compound ID CG JWH-030 
5.80 Naphthalene V 2B P, S 
7.88 1,4-Naphthalenedione T - P, S 
8.47 Acenaphthylene T - S 
8.85 1-Naphthalenecarboxaldehyde T - P, S 
8.89 1-Naphthalenol T - P, S 
8.95 2-Naphthalenol T - P 
9.53 1-(1-Naphthalenyl)ethanone T - P, S 
9.86 2H-Naphtho[1,8-bc]furan-2-one T - P, S 
9.90 1-Dimethoxylmethylnaphthalene T - P 
9.96 2-Naphthalenecarboxylic acid methyl ester T - P, S 
10.39 1-Naphthalenecarboxylic acid T - P, S 
10.55 2-Naphthalenecarboxylic acid T - P 
11.28 Anthracene V 3 P 
11.59 1-Naphthamide T - P 
12.03 1H-Phenalen-1-one V - P, S 
13.96 2-Phenylindole-3-carboxaldehyde T - P 
14.35 N-Pentyl-2-naphthamide T - P, S 
15.45 5(4H)-Thebenidinone T - P 
17.00 JWH-030 V - P, S 
Identification (ID) refers to whether the pyrolytic product was tentatively identified, T, or verified with a 
reference material, V. The carcinogenic group (CG) indicates the IARC classification to which the analyte 
belongs [1, 2A, 2B, 3, or 4]. The extract in which the pyrolytic product is indicated with a single capital 
letter representative of each of the three extracts: W (wool), P (pipette), and S (solvent layer). 
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Figure 43: Proposed pyrolytic products of JWH-030 
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Figure 43 continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
113 
 
4.3.2 PYROLYSIS OF JWH-018 
The presence of an additional benzene ring is the only structural difference between 
JHW-018 (indole) and JWH-030 (pyrrole). This minor but significant structural 
appendage was expected to have a profound effect on the type of products observed 
with JWH-018 than were noticed with JWH-030. From a broad perspective, it was 
expected that a greater proportion of products identified with 3-naphthoylindole and 
indole compounds would be present because of the indole, and consequently 
naphthoyl-indole, moiety that JWH-018 does possess. Overall, there were fifty-two 
pyrolytic products identified with JWH-018 (see Table 12 and Figure 44). 
Nineteen of the fifty-two products identified with JWH-018 were also observed in the 
previous chapter with the indole-compounds (not independent of other analytes 
pyrolyzed); representing a proportionally greater amount compared to that of JWH-030. 
Seven JWH-018 pyrolytic products (isoquinoline, 1-(2-aminophenyl)ethanone, 2(1H)-
quinolinone, 1-pentylindole, indole-3-carboxaldehyde, and both 2- and 3-
methylcarbazole) were found exclusively in the indole extracts. Another six compounds 
(1,2-naphthalenedione, naphthalene-1-carbonitrile, chrysene, N-(1-naphthoyl)-sarcosine 
ethyl ether and dibenzo(b,def)carbazole) were exclusively identified in the 3-
naphthoyldinole extracts. There does not appear to be significant enough difference 
between the products that are observed with JWH-018 and JWH-030 and the different 
moieties that they contain. 
There were five JWH-018 pyrolytic products (4-isocyanatoacetophenone, 5- and 7-
hydroxy-1-naphthalenecarbonitrile, 1-naphthoic acid 3-methylbutyl ester, and 
benz[a]anthracene-7-carbonitrile) that were not observed with the non-controlled 
substances. The utility that the two hydroxy-1-naphthalenecarbonitrile species and 1-
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naphthoic acid 3-methylbutyl ester may have as pyromarkers of the synthetic 
cannabinoid JWH-018 is uncertain. Although none of these were identified with the 
other three synthetic cannabinoids and vice versa, the hydroxylated naphthalene 
species may consequently be a metabolite and esters are rapidly hydrolyzed within the 
body and would likely not be detectable for a needed duration. Additionally, the 
synthetic cannabinoid JWH-071 (ethyl-analog of JWH-018) was identified as a product. 
Although not suitable as a pyromarker, the identification of another synthetic 
cannabinoid suggests that pyrolysis may consequently result in an individual being 
exposed to multiple receptor agonists. 
In addition to JWH-071 being identified, there were three pyrolytic products from 
JHW-018 that were not able to be identified, but contain characteristic m/z ions of 155 
and 127 which make them potentially valuable targets (see Appendix H). The unknown 
at 17.05 minutes is second in abundance to only JWH-018 itself, but due to minimal 
fragmentation it is difficult to predict the identity of this compound. The unknown has a 
molecular ion of m/z 283, but the intensity of the m/z 155 and 127 ions dominates the 
spectra. The existence of such fragmentation implies that the connectivity to the 
naphthoyl core is weak and could possibly suggest that the molecular structure contains 
a nitrogen atom in an adjacent position. 
The unknown pyrolytic product eluting at 17.36 minutes was of considerably less 
abundance compared to the previous, but is an interesting notion. The spectral 
databases provided a match to that of 3-naphthoylindole but the retention time is 
inconsistent with that of the reference material. The unknown does have ions consistent 
with 3-naphthoylindole but the ratio of the m/z 144 is much different and a noticeable 
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difference is observed with the m/z 116 ion as well. It is possible that this compound is a 
1’-naphthyl or 2-naphthoyl isomer for which a reference material was not available to 
compare a retention and spectrum with. 
The final unknown pyrolytic product which showed ions characteristic of synthetic 
cannabinoids was observed at 20.78 minutes. The molecular ion of this unknown is 
believed to be m/z 339 and has reasonable consistency with that of another synthetic 
cannabinoid, JHW-022. However, a drastic difference in the abundance of the m/z 310 
ion is noticed; much greater with the unknown than that of JWH-022. Additionally, there 
is an appreciably abundant ion at m/z 214 which is not found in JWH-022. This 
compound is likely to be very structurally similar to JWH-022 but was unable to be 
definitely characterized in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
116 
 
Table 12: Pyrolytic products identified from investigation of JWH-018 
Retention 
Time (min) 
Compound ID CG JWH-018 
3.42 Phenol T 3 P 
4.19 3-Methylphenol T - P 
4.95 Benzyl nitrile T - P 
5.61 3-Phenyl-2-propenenitrile T - P 
5.68 1,2-Naphthalenedione T - P 
5.80 Naphthalene V 2B P 
6.26 Quinoline V - P, S 
6.50 Isoquinoline T - P 
6.84 1-(2-Aminophenyl)ethanone T - P 
6.99 1-Methylnaphthalene V - P 
6.73 Indole V - S 
7.02 2-Methylquinoline T - P 
7.16 2-Methylnaphthalene T - P 
7.49 4-Isocyanatoacetophenon T - W, S 
7.53 3-Methylquinoline V - P 
7.63 2(1H)-Quinolinone T - P 
7.88 1,4-Naphthalenedione T - P 
8.01 1-Ethylnaphthalene V - P 
8.13 2-Ethenylnaphthalene T - P 
8.34 Oxindole V - P 
8.48 Acenaphthylene T - P 
8.75 Naphthalene-1-carbonitrile T - P 
8.80 Acenaphthene V - P 
8.86 1-Naphthalenecarboxaldehyde T - P 
8.89 1-Naphthalenol T - P 
9.28 1(2H)-Acenaphthylenone T - P 
9.87 1-Pentylindole V - P, S 
9.94 2-Naphthalenecarboxylic acid methyl ester T - S 
10.05 5-Hydroxy-1-naphthalenecarbonitrile T - P 
10.18 Dibenzofuran  T - P 
10.44 7-Hydroxy-1-naphthalenecarbonitrile T - P 
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11.05 Indole-3-carboxaldehyde V - P 
11.27 Anthracene V 3 P 
11.55 Carbazole T - P 
11.83 1-(Phenylmethylene)indene T - P 
12.05 1H-Phenalen-1-one V - P 
12.17 3-Methylcarbazole T - P 
12.37 2-Methylcarbazole T - P 
12.67 1-Phenylnaphthalene T - P 
12.92 3-Methylbutyl ester 1-naphthoic acid T - P 
13.32 Fluoranthene V 3 P 
14.29 11H-Benzo[b]fluorene T 3 P 
14.60 Chrysene T 3 P 
15.69 11H-Benzo[a]carbazole T - P 
15.75 Naphthacene T - P 
15.83 1,2’-Binaphthalene T - P 
16.11 N-(1-Naphthoyl)-sarcosine ethyl ester T - P, S 
16.57 Dibenzo(b,def)carbazole T - P 
17.71 Benz[a]anthrancene-7-carbonitrile T - S 
18.48 JWH-071 T - P 
18.95 3-(1-Naphthoyl)indole V - W, P 
20.31 JWH-018 V - W, P, S 
Identification (ID) refers to whether the pyrolytic product was tentatively identified, T, or verified with a 
reference material, V. The carcinogenic group (CG) indicates the IARC classification to which the analyte 
belongs [1, 2A, 2B, 3, or 4]. The extract in which the pyrolytic product is indicated with a single capital 
letter representative of each of the three extracts: W (wool), P (pipette), and S (solvent layer). 
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Figure 44: Proposed pyrolytic products of JWH-018 
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Figure 44 continued 
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Figure 44 continued 
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4.3.3 PYROLYSIS OF JWH-081 
Of the four synthetic cannabinoids that were studied, JWH-081 was the only one 
with an additional oxygen-atom outside of the carbonyl group. JWH-081 also happens 
to be the highest molecular weight compound of the group being investigated; 
structurally differing from JWH-018 only in that it possesses a 4-methoxy-naphthyl 
substituent where JWH-018 has a hydrogen atom. In the previous chapter, it was 
determined that the greatest number of identifiable pyrolytic products stemmed from the 
pyrolysis of 1-methoxynaphthalene (73) and the same trend was observed among the 
synthetic cannabinoids with sixty-three products being identified with JWH-081 (see 
Table 13 and Figure 45).  
With the methoxy-naphthyl moiety, it was suspected that an increased number of the 
pyrolytic products from 1-methoxynaphthalene would also be identified in the JWH-081 
extracts. However, only five of the thirty-three pyrolytic products that were exclusive to 
1-methoxynaphthalene (in Table 8) were identified with JWH-018. This was slightly 
more than the two (3-methylquinoline and 11H-benzo[b]fluorene) identified in the JWH-
018 extracts and there were no such products identified in the JWH-030 extracts. Of 
these particular compounds, the three products observed with JWH-081 (1,1’-biphenyl-
4-carboxaldehyde, 2-hydroxyfluorene, and dinaphtho[1,2-b:1’,2’-d]furan) were 
oxygenated species; unlike the two previously mentioned products. 
There were seventeen pyrolytic products identified with JWH-081 that were not 
observed with any of the non-controlled substances (including 1-methoxynaphthalene). 
Additionally, the isocyanatoacetophenone species at 7.49 minutes was the only 
pyrolytic product that was identified in either JWH-018 or JWH-030. After eliminating the 
compounds that were identified with UR-144, there were twelve compounds exclusively 
122 
 
identified as pyrolytic products of JWH-081: 1- and 3-methylisoquinoline, isoquinoline-1-
carbonitrile, 2-ethenylquinoline, 2,4-dimethylquinoline, 3-phenylpyridine, 4-
hydroxymethyl-naphthalen-1-one, 1-naphthalenol acetate, 7-methyl-1-naphthalenol, 
phenanthridine, 9-phenylacridine, and benz(a)acridine. 
Similar to the type of products observed with JWH-018, there are a number of 
chemicals that may potentially cause detrimental health effects. Four particular 
compounds are classified as Group 2B carcinogens and another six are listed in Group 
3. A number of substituted quinoline and isoquinoline species were identified that may 
be cause for concern given that quinoline is listed as a probable human carcinogen by 
the NTP. Additionally, JWH-018 was identified in the extracts of JWH-081, indicating 
that the methoxy-group is susceptible to bond cleavage. 
A current review of scientific literature indicates that one article and one abstract 
have examined the possibility that burning one synthetic cannabinoid can consequently 
generate additional synthetic cannabinoids [97, 98]. A 2013 study by Donohue et. al. 
showed that the synthetic cannabinoids JWH-018 and JWH-022 (4-pentenyl analog of 
JWH-018) were identifiable in the charred remains of the synthetic cannabinoid AM-
2201 (N-pentyl fluorine analog of JWH-018). This idea was followed up with in a 2014 
abstract by RTI International which reported identifying JWH-022 as a pyrolytic product 
of JWH-018, five products (including JWH-018 and JWH-022) as a result of AM-2201, 
and JWH-167 as a result of JWH-250. JWH-167 and JWH-250 which belong to the 
phenylacetyl-indole class of cannabimimetics are analogous to naphthoyl-indoles JWH-
018 and JWH-081 and correlate with the observations of this study. 
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There were four pyrolytic products at 17.06 minutes, 19.05 minutes, 21.54 minutes 
and 21.74 minutes that could not be identified (see Appendix H). The first of these 
unknowns was previously discussed in the section with JWH-018. A small peak at 19.05 
minutes was unable to be structurally elucidated based upon limited fragments. The 
molecular ion of this unknown is presumed to be the m/z ion at 313, which could 
suggest a molecular structure consistent with that of JWH-072 (the propyl analog of 
JWH-018). However, the relative intensity of the molecular ion peak in the unknown is 
significantly lower than that of JWH-072. The base peak of m/z 185 did not afford much 
assistance in structural elucidation of this compound and this compound has therefore 
been included as an unidentified pyrolytic product of interest. 
The third and fourth unknown products at 21.54 and 21.74 minutes partially co-
eluted with each other. The compound at 21.54 minutes has a prominent molecular ion 
of m/z 301. The second base peak was m/z 144, which would lead one to believe that 
an indolyl-moiety is present. A possible molecular structure for this unknown could be a 
3-naphthoylindole core with a carboxaldehyde substituent replacing the methoxy-group, 
but further consideration would need to be taken in structurally elucidating this 
unknown. The last unknown compound was identified because of a large base peak of 
m/z 214 and the second most intense ion being m/z 144. The presence of each ion 
implies that the molecule contains an indolyl-moiety with an attached pentyl-group. 
However, there was difficulty identifying the substituents of this core without abundant 
higher m/z ions in the spectra. 
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Table 13: Pyrolytic products identified during investigation of JHW-081 
Retention 
Time (min) 
Compound ID CG JWH-081 
6.26 Quinoline V - P, S 
6.49 Isoquinoline T - P 
6.73 Indole V - P, S 
7.02 2-Methylquinoline T - P 
7.36 1-Methylisoquinoline T - P 
7.49 3-Isocyanatoacetophenone T - P 
7.53 3-Methylquinoline V - P 
7.68 2-Methylindole T - P 
7.71 4-Methylquinoline T - P, S 
7.90 1,4-Naphthalenedione T - P, S 
8.19 Isoquinoline-1-carbonitrile T - P 
8.26 2-Ethenylquinoline T - P 
8.36 2,4-Dimethylquinoline T - P 
8.63 3-Phenylpyridine T - P 
8.66 3-Methylisoquinoline T - P 
8.73 Naphthalene-1-carbonitrile T - P 
8.87 1-Naphthalenol T - P, S 
8.95 Naphthalene-2-carbonitrile V - P 
9.15 4-Hydroxy-methyl-naphthalen-1-one T - P 
9.28 1(2H)-Acenaphthylenone T - P, S 
9.46 Indole-5-carbonitrile T - P 
9.49 1-Naphthalenol acetate T - P 
9.83 7-Methyl-1-naphthalenol T - P 
9.87 1-Pentylindole V - P, S 
10.19 Dibenzofuran T - P 
10.30 1,1'-Biphenyl-4-carboxaldehyde T - P 
10.42 2-Hydroxyfluorene T - P 
10.59 1-Pentyl-2-methylindole T - P 
10.87 9H-Fluoren-9-one T - P 
11.02 3,5-Dimethyl-2-phenylpiperidin-4-one T - P 
11.06 Indole-3-carboxaldehyde V - P 
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11.28 Anthracene V 3 P, S 
11.37 Phenanthrene T 3 P 
11.39 Benzo[f]quinoline T - P 
11.55 Carbazole T 2B P, S 
11.74 Phenanthridine T - P 
11.83 1-(Phenylmethylene)indene T - P 
12.04 1H-Phenalen-1-one V - P 
12.16 3-Methylcarbazole T - P 
12.36 2-Methylcarbazole T - P 
12.49 9-Methylcarbazole T - P 
12.66 1-Phenylnaphthalene T - P 
13.32 Fluoranthene V 3 P 
13.46 9-(Cyanomethylene)fluorene T - P 
13.67 Pyrene T 3 P 
13.72 Benzo[b]naphtho[2,3-d]furan T - P 
14.29 11H-Benzo[b]fluorene T 3 P 
14.41 7H-Benzo[c]fluorene T - P 
14.59 Chrysene T 3 P 
15.36 Benzo[c]phenanthrene T 2B P 
15.44 9-Phenylacridine T - P 
15.65 Benz(a)acridine T - P 
15.68 11H-Benzo[a]carbazole T - P 
15.72 Benz[a]anthracene V 2B P 
15.77 Naphthacene T - P, S 
15.83 1,2'-Binaphthalene T - P 
15.96 Naphtho(2,1-f)quinoline T - P 
16.02 1-Aminopyrene T - P 
16.56 Dibenzo(b,def)carbazole T - P 
17.47 Benzo[k]fluoranthene T 2B P 
17.53 Dinaphtho[1,2-b:1',2'-d]furan T - P, S 
20.32 JWH-018 V - P 
23.48 JWH-081 V - P, S 
Identification (ID) refers to whether the pyrolytic product was tentatively identified, T, or verified with a 
reference material, V. The carcinogenic group (CG) indicates the IARC classification to which the analyte 
belongs [1, 2A, 2B, 3, or 4]. The extract in which the pyrolytic product is indicated with a single capital 
letter representative of each of the three extracts: W (wool), P (pipette), and S (solvent layer). 
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Figure 45: Proposed pyrolytic products of JWH-081 
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Figure 45 continued 
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Figure 45 continued 
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Figure 45 continued 
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4.3.4 PYROLYSIS OF UR-144 
Forty-eight compounds were identified as pyrolytic products of the synthetic 
cannabinoid UR-144. The overall dissimilarity these products had from those identified 
in the other synthetic cannabinoid enables a number of compounds to be suggested as 
possible pyromarkers of UR-144. Five of the total UR-144 products were identified in 
the naphthalene-containing compounds, but only one (3-methylquinoline) was solely 
identified in the extracts from the naphthalene-compounds. This correlates with the 
absence of a naphthalene group in UR-144.  
The absence of naphthalene appears to have a direct effect on the number of 
products which pose a carcinogenic threat to users. Carbazole (Group 2B) and 
fluoranthene (Group 3) were detected, but with fluoranthene being the only compound 
identified which had more than three fused rings, no other health hazards can be 
explicitly provided without future research first being conducted on the health hazards of 
the number of substituted PAHs that were observed.  
UR-144 had the largest percentage of compounds (57%) that were only identified in 
its extracts when compared to the others. Of the twenty-eight products identified only 
with UR-144, twenty-two were not identified with the non-controlled compounds studied 
in the previous chapter. Table 14 shows the total list of pyrolytic products that were 
identified and the corresponding structures are provided in Figure 46. 
 
 
 
 
131 
 
Table 14: Pyrolytic products identified during investigation of UR-144 
Retention 
Time (min) 
Compound ID CG UR-144 
3.37 Isocyanatobenzene T - P 
3.44 Aniline T - P 
4.92 Dihydro-4,4,5,5-tetramethyl-2(3H)furanone T - P, S 
6.51 Isoquinoline T - P, S 
6.76 Indole V - P, S 
6.80 N-Phenylformamide T - P 
7.02 2-Methylquinoline V - S 
7.29 2-Aminobenzoic acid methyl ester T - P 
7.47 N-Phenylacetamide T - P 
7.49 4-Isocyanatoacetophenone T - P, S 
7.53 3-Methylquinoline T - P, S 
7.63 2(1H)-Quinolinone T - P 
7.69 2-Methylindole T - P 
7.71 4-Methylquinoline T - S 
8.14 1-Methyl-2-indolinone T - P 
8.33 Oxindole V - P, S 
8.55 2,3-Dimethylphenylisocyanate T - S 
8.63 2,4,6-Trimethylbenzonitrile T - P 
8.76 N-Acetylindole T - P, S 
8.88 Naphthalene-1-carbonitrile T - P 
8.94 Naphthalene-2-carbonitrile V - P, S 
9.33 2-Acetylindole T - P, S 
9.39 3-Propylquinoline T - P 
9.46 N-Ethyl-1-naphthalenamine T - P, S 
9.81 Indole-3-ethanol T - P 
9.88 1-Pentylindole V - P, S 
10.01 1-Isocyanatonaphthalene T - P, S 
10.18 Isatin V - P, S 
10.27 1H-Cyclopenta[b]quinoxaline-1,2,3-trione T - P 
10.35 6-(1-Methylpropyl)quinoline T - P, S 
10.44 7-Hydroxy-2-naphthalenecarbonitrile T - P 
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10.59 1-Pentyl-2-methylindole T - P 
11.00 3,5-Dimethyl-2-phenylpiperidin-4-one T - P, S 
11.05 Indole-3-carboxaldehyde V - P, S 
11.29 4'-(1-Pyrroyl)acetophenone T - P, S 
11.39 Acridine T - P, S 
11.55 Carbazole T 2B P, S 
11.61 1-(1H-Indol-3-yl)ethanone T - P 
11.74 1-Methyl-3-acetylindole T - P 
12.17 3-Methylcarbazole T - P 
12.37 2-Methylcarbazole T - P, S 
12.49 9-Methylcarbazole T - P 
12.94 1,4-Dimethylcarbazole T - P 
13.32 Fluoranthene V 3 P 
13.44 3,4-Dimethylcarbazole T - P, S 
15.17 10-Pentyl-10H-acridin-9-one T - P, S 
16.02 UR-144 V - P, S 
16.18 UR-144 Degradant V - P, S 
Identification (ID) refers to whether the pyrolytic product was tentatively identified, T, or verified with a 
reference material, V. The carcinogenic group (CG) indicates the IARC classification to which the analyte 
belongs [1, 2A, 2B, 3, or 4]. The extract in which the pyrolytic product is indicated with a single capital 
letter representative of each of the three extracts: W (wool), P (pipette), and S (solvent layer). 
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Figure 46: Proposed pyrolytic products for UR-144 
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Figure 46 continued 
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Figure 46 continued 
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There were four specific pyrolytic products that were unable to be tentatively 
identified or verified with reference materials and are thus not listed in the data table. 
Plausible structures and names for two of the unknown compounds have been 
proposed based upon the mass spectral fragmentation patterns observed. The first 
unknown pyrolytic product (UPP1) which eluted at 13.62 minutes was the second most 
abundant product observed in the pyrogram; the most abundant product being the UR-
144 Degradant at 16.18 minutes. The combined pyrogram and mass spectra for UPP1 
is provided in Figure 47. The molecular ion and base peak for UPP1 were determined 
to be m/z 229 and m/z 214, respectively. The proposed fragmentation pathway for 
UPP1 is provided in Figure 48 and provides plausible explanations for the m/z 144, 
172, and 130. 
A structure has also been proposed for a second unknown pyrolytic product (UPP2) 
which was identified at 14.10 minutes. The combined pyrogram and mass spectra for 
UPP2 is provided in Figure 49, with the proposed fragmentation pathway illustrated in 
Figure 50. The molecular ion, m/z 243, and base peak, m/z 214, of UPP2 suggest 
similarity to that of UPP1. The m/z 144 fragment ion was also used when proposing a 
molecular structural for this product. 
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Figure 47: Pyrogram and mass spectrum for UPP1 
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Figure 48: Proposed fragmentation pattern for UPP1 
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Figure 49: Pyrogram and mass spectrum for UPP2 
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Figure 50: Proposed fragmentation pathway for UPP2 
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Structural interpretation for the two other unknown pyrolytic products identified at 
15.23 minutes (UPP3) and 16.79 minutes (UPP4) was unsuccessful. UPP4 was the 
third most abundant product observed in the UR-144 pyrogram and showed spectral 
similarity to that of UR-144 and the UR-144 Degradant. A low intensity molecular ion of 
m/z 311, with an even lower intensity ion with m/z 296, was observed in the mass 
spectrum for this unknown. The base peak ion with m/z 229 suggests that the 1-pentyl-
3-acetylindole moiety is present in this particular pyrolytic product and that the carbon-
carbon bond connecting the rest of the molecular structure is highly susceptible to bond 
cleavage. 
UPP3 was found to contain the characteristic ions (m/z 311 molecular ion and 
fragment ion m/z 296 ion) for a compound related to UR-144 or the UR-144 Degradant 
(see Appendix L). Unlike the UPP4, the base peak of the spectra was the m/z 296 ion, 
which corresponds to the loss of a methyl radical. All additional ions (m/z 252, 210, 180, 
167, 144, 130, and 109) in the spectra were of considerably low intensity and suggest 
that the pyrolytic product is relatively capable of stabilizing the excess energy imparted 
during the ionization process (i.e. extensive conjugation or aromaticity). 
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4.4.0 CONCLUSION 
The pyrolysis of four synthetic cannabinoids has confirmed the presence of pyrolytic 
products observed with that of the smaller components investigated in the previous 
study. Compared to the results from the indole and naphthalene containing compounds, 
a similar number of pyrolytic products were observed with each synthetic cannabinoid. 
The greatest number of pyrolytic products was identified with 1-methoxynaphthalene 
and JHW-081, suggesting that a molecule containing a methoxy group will be more 
reactive than other similar compounds without the functional group. The fewest number 
of products were identified with 1-methylnaphthalene and JWH-030, indicating the 
relatively unreactive nature of a lone methyl-substituent connected to an aromatic 
system.  
Ranging from phenol to chrysene, there were a number of compounds generated 
during the pyrolysis of the synthetic cannabinoids which are considered to be serious 
health hazards; excluding UR-144. Such compounds with a varying level of 
carcinogenic concern, as defined by IARC, may pose serious long-term health effects to 
chronic users of synthetic cannabinoids. The unknown health effects of the remaining 
pyrolytic products (heterocyclic amines, etc.) are also concerning.  
While not every product was able to be identified, it was found that structurally 
similar synthetic cannabinoids could be generated during pyrolysis; as was evident with 
the result of JWH-018 and JWH-081. With the possibility that more than one synthetic 
cannabinoid already exists in herbal incense products, the generation of multiple 
biologically active compounds could be contributing to the severe effects observed with 
the use of these particular designer drugs. 
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FUTURE DIRECTIONS 
Future work should begin with the structural elucidation of the specified unknown 
pyrolytic products of JWH-030, JWH-018, JHW-081, and UR-144 discussed in Chapter 
4. The ability to characterize these specific compounds may lead to the identification of 
potential pyromarkers and/or biologically active compounds. Identifying unique 
pyromarkers of these drugs would provide forensic toxicologists with a valuable analyte 
that, in the absence of the parent drug, can indicate use of a given substance. 
Investigating the acute and chronic effects of the most abundant pyrolytic products is 
another potential avenue for continued research. While this work is strictly qualitative, 
future work could include the verification and quantification of levels associated with the 
pyrolytic product(s) of interest using reference materials. Cell cultures could then be 
dosed with a corresponding concentration to assess toxicity or other desired cellular 
responses and outputs. The bind affinity of the prominent pyrolytic products for both the 
CB1 and CB2 receptors would also be beneficial information that has not yet been 
reported. 
One additional area of interest would be to pyrolyze the plant material that synthetic 
cannabinoids are commonly sprayed onto. While the synthetic cannabinoids are 
typically viewed as the primary ingredient of herbal incense products and are certainly 
the main focus of forensic chemists, the pyrolysis of the plant material would provide 
insight regarding the generation of other potentially harmful compounds. 
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APPENDIX A – AMOUNT OF EACH NON-CONTROLLED SUBSTANCE 
PYROLYZED 
 
 
Listed below is the amount of chemical substance that was pyrolyzed in each trial. Also 
included is the amount of quartz wool that was used to ‘sandwich’ the chemical. For 
liquid analytes, the pipettes were allowed to air-dry overnight (~18 hours) before 
pyrolysis. 
 
 
Naphthalene 
 Bottom Plug of Wool Chemical Top Plug of Wool 
Trial #1 64.61 mg 5.46 mg 16.32 mg 
Trial #2 59.62 mg 5.67 mg 25.39 mg 
Trial #3 46.52 mg 7.34 mg 22.69 mg 
 
1-Methylnaphthalene (density = 1.001 g/mL) 
 Bottom Plug of Wool Chemical Top Plug of Wool 
Trial #1 62.48 mg 40 µL 13.50 mg 
Trial #2 61.36 mg 40 µL 24.08 mg 
Trial #3 69.71 mg 40 µL 20.96 mg 
 
1-Methoxynaphthalene (density = 1.094 g/mL) 
 Bottom Plug of Wool Chemical Top Plug of Wool 
Trial #1 60.64 mg 40 µL 11.06 mg 
Trial #2 59.01 mg 40 µL 15.88 mg 
Trial #3 70.16 mg 40 µL 15.79 mg 
 
1-Ethylnaphthalene (density = 1.008 g/mL) 
 Bottom Plug of Wool Chemical Top Plug of Wool 
Trial #1 55.81 mg 40 µL 21.16 mg 
Trial #2 59.05 mg 40 µL 15.45 mg 
Trial #3 60.26 mg 40 µL 19.69 mg 
 
Indole 
 Bottom Plug of Wool Chemical Top Plug of Wool 
Trial #1 62.47 mg 8.48 mg 11.16 mg 
Trial #2 57.35 mg 9.86 mg 15.90 mg 
Trial #3 55.21 mg 5.06 mg 22.64 mg 
 
3-Methylindole  
 Bottom Plug of Wool Chemical Top Plug of Wool 
Trial #1 51.05 mg 5.29 mg 15.75 mg 
Trial #2 48.98 mg 6.18 mg 15.73 mg 
Trial #3 49.51mg 5.80 mg 19.78 mg 
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1-Pentylindole 
 Bottom Plug of Wool Chemical Top Plug of Wool 
Trial #1 52.57 mg 40 µL 18.45 mg 
Trial #2 51.21 mg 40 µL 15.44 mg 
Trial #3 45.29 mg 40 µL 23.63 mg 
 
Indole-3-Carboxaldehyde 
 Bottom Plug of Wool Chemical Top Plug of Wool 
Trial #1 48.35 mg 4.99 mg 14.24 mg 
Trial #2 50.70 mg 4.47 mg 14.71 mg 
Trial #3 44.04 mg 4.87 mg 19.10 mg 
 
3-Naphthoylindole 
 Bottom Plug of Wool Chemical Top Plug of Wool 
Trial #1 56.65 mg 3.99 mg 17.77 mg 
Trial #2 50.52 mg 3.12 mg 23.65 mg 
Trial #3 50.08 mg 4.43 mg 23.01 mg 
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APPENDIX B – TIC OF INDOLE-3-CARBOXALDEHYDE, 1-PENTYLINDOLE, AND 3-
NAPHTHOYLINDOLE STANDARDS 
 
 
Qualitative EI GC-MS total ion chromatogram and mass spectrum for the indole-3-carboxaldehyde standard 
 
Indole-3-carboxaldehyde was provided for this project via in-house synthesis (without an associated purity). The lone 
impurity detected at 11.53 minutes was identified as indole-3-carboxylic acid methyl ester using the NIST 2014 database 
(mass spectrum not shown). 
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Qualitative EI GC-MS total ion chromatogram and mass spectrum for the 1-pentlyindole standard 
 
1-pentylindole was provided for this project via in-house synthesis (without an associated purity). The impurities present at 
6.73, 10.69, and 11.00 minutes were identified as indole, 1-pentyl-3-methylindole, and 3,5-dimethyl-2-phenylpiperidin-4-
one using the NIST 2014 MS database (individual mass spectra not shown). 
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Qualitative EI GC-MS total ion chromatogram and mass spectrum for the 3-naphthoylindole standard 
 
3-naphthyolindole was also provided for this project via in-house synthesis (without an associated purity). Trace amounts 
of indole at 6.74 min, N-Methyl-2-naphthamide at 10.28 min, and 1,4-dihydro-1,4-methanonaphthalene-6-carboxylic acid 
at 11.41 min were identified using the NIST 2014 MS library (not displayed in the given figure above). A small impurity, 
that was unable to be identified (base peak m/z 305; secondary base peak m/z 288), at 20.80 minutes did exist but was 
considered negligible. 
 
157 
 
APPENDIX C – PYROGRAMS REPRESENTATIVE OF THE MATRIX COMPONENTS IN BLANK WOOL 
AND BLANK SOLVENT LAYER EXTRACTS 
 
 
EI GC-MS total ion chromatogram showing the matrix components present in a blank wool extract
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EI GC-MS total ion chromatogram showing the matrix components present in a blank wool extract 
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APPENDIX D - AMOUNT OF EACH SYNTHETIC CANNABINOID 
PYROLYZED 
 
 
Listed below is the amount of each controlled substance that was pyrolyzed in each 
trial. Also included is the amount of quartz wool that was used to ‘sandwich’ the 
chemical. 
 
 
JWH-030 
 Bottom Plug of Wool Chemical Top Plug of Wool 
Trial #1 64.61 mg 75 µL 16.32 mg 
Trial #2 59.62 mg 75 µL 25.39 mg 
Trial #3 46.52 mg 75 µL 22.69 mg 
Due to limit quantity of the JWH-030 standard, only 75 microliters of the 20 mg/mL standard 
were used per trial. Samples were allowed to air dry (overnight) before pyrolysis. 
 
JWH-018 
 Bottom Plug of Wool Chemical Top Plug of Wool 
Trial #1 51.6 mg 5.46 mg 24.4 mg 
Trial #2 51.0 mg 5.67 mg 26.1 mg 
Trial #3 48.9 mg 7.34 mg 22.2 mg 
 
JWH-081 
 Bottom Plug of Wool Chemical Top Plug of Wool 
Trial #1 49.9 mg 5.0 mg 18.2 mg 
Trial #2 51.5 mg 4.8 mg 18.9 mg 
Trial #3 48.2 mg 5.6 mg 20.1 mg 
 
UR-144 
 Bottom Plug of Wool Chemical Top Plug of Wool 
Trial #1 50.6 mg 5.1 mg 23.5 mg 
Trial #2 58.2 mg 5.4 mg 17.2 mg 
Trial #3 49.9 mg 5.0 mg 20.9 mg 
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APPENDIX E - PYROGRAMS REPRESENTATIVE OF JWH-030 
 
 
 
Pyrogram representative of the JWH-030 wool extract
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Pyrogram representative of the JWH-030 pipette extract 
 
Zoomed in versions of this pyrogram can be found on the following two pages 
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The first of two pyrograms from the JWH-030 pipette extract which have been magnified to enlarge details 
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The second of two pyrograms from the JWH-030 pipette extract which have been magnified to enlarge details 
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Pyrogram representative of the JWH-030 solvent layer extract 
 
Zoomed in versions of this pyrogram can be found on the following two pages
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The first of two pyrograms from the JWH-030 solvent layer extract which have been magnified to enlarge details 
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The second of two pyrograms from the JWH-030 solvent layer extract which have been magnified to enlarge details 
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APPENDIX F – CHROMATOGRAPHIC AND MASS SPECTRAL INFORMATION OF THE UNIDENTIFIED 
JWH-030 PYROLYTIC PRODUCTS 
 
 
 
 
 
 
 
 
Chromatographic display (pyrogram; top) for the first three unidentifiable pyrolytic products at 13.15, 13.25, and 13.90 minutes; 
and mass spectra results of the unknown at 13.15 minutes 
 
Spectra for the other four pyrolytic products are provided on the following two pages 
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Mass spectra for the pyrolytic products at 13.25 and 13.90 minutes (see above page for magnified image of pyogram) 
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Chromatographic display (pyrogram; top) and mass spectral results of the two unidentifiable pyrolytic products at 17.23 minutes 
(top) and 17.51 minutes (bottom)
170 
 
APPENDIX G – PYROGRAMS REPRESENTATIVE OF JWH-018 
 
 
Pyrogram representative of the JWH-018 wool extract 
 
Zoomed in versions of this pyrogram can be found on the following two pages 
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The first of two pyrograms from the JWH-018 wool extract which have been magnified to enlarge details 
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The second of two pyrograms from the JWH-018 wool extract which have been magnified to enlarge details 
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Pyrogram representative of the JWH-018 pipette extract 
 
Zoomed in versions of this pyrogram can be found on the following two pages 
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The first of two pyrograms from the JWH-018 pipette extract which have been magnified to enlarge details 
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The second of two pyrograms from the JWH-018 pipette extract which have been magnified to enlarge details 
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Pyrogram representative of the JWH-018 solvent layer extract 
 
Zoomed in versions of this pyrogram can be found on the following two pages 
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The first of two pyrograms from the JWH-018 solvent layer extract which have been magnified to enlarge details 
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The second of two pyrograms from the JWH-018 solvent layer extract which have been magnified to enlarge details 
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APPENDIX H – CHROMATOGRAPHIC AND MASS SPECTRAL INFORMATION OF THE UNIDENTIFIED 
JWH-018 PYROLYTIC PRODUCTS 
 
 
Chromatographic display (pyrogram; top) for the first unidentifiable pyrolytic product at 17.05, 17.37, and 20.78 minutes and mass 
spectra results of this unknown at 17.05 minuets 
 
Data for the other two pyrolytic products are provided on the following page 
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Mass spectra for the pyrolytic products at 17.39 and 20.78 minutes (see above page for magnified image of pyogram) 
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APPENDIX I – PYROGRAMS REPRESENTATIVE OF JWH-081 
 
 
Pyrogram representative of the JWH-081 wool extract 
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Pyrogram representative of the JWH-081 pipette extract 
 
Zoomed in versions of this pyrogram can be found on the following two pages 
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The first of two pyrograms from the JWH-081 pipette extract which have been magnified to enlarge details 
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The second of two pyrograms from the JWH-081 pipette extract which have been magnified to enlarge details 
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Pyrogram representative of the JWH-081 solvent layer extract  
 
Note: two of the three solvent layer extracts for JWH-081 showed significantly lower levels than the other synthetic cannabinoids 
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APPENDIX J – CHROMATOGRAPHIC AND MASS SPECTRAL INFORMATION OF THE UNIDENTIFIED 
JWH-081 PYROLYTIC PRODUCTS 
 
 
Chromatographic display (pyrogram; top) for the four unidentifiable pyrolytic products at 17.07, 19.05, 21.54, and 21.74 minutes; 
the mass spectra of the unknown at 17.07 minutes has also been provided above 
 
Data for the other three pyrolytic products are provided on the following two pages 
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Mass spectra for the pyrolytic products at 19.05 and 21.54 minutes (see previous page for magnified image of pyrogram) 
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Mass spectra for the pyrolytic product at 21.74 minutes (magnified image of pyrogram provided above) 
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APPENDIX K – PYROGRAMS REPRESENTATIVE OF UR-144 
 
 
 
Pyrogram representative of the UR-144 wool extract 
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Pyrogram representative of the UR-144 pipette extract 
 
Zoomed in versions of this pyrogram can be found on the following two pages 
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The first of two pyrograms from the UR-144 pipette extract which have been magnified to enlarge details 
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The second of two pyrograms from the UR-144 pipette extract which have been magnified to enlarge details 
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Pyrogram representative of the UR-144 solvent layer extract 
 
Zoomed in versions of this pyrogram can be found on the following two pages 
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The first of two pyrograms from the UR-144 pipette extract which have been magnified to enlarge details 
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The first of two pyrograms from the UR-144 pipette extract which have been magnified to enlarge details
196 
 
APPENDIX L – CHROMATOGRAPHIC AND MASS SPECTRAL INFORMATION OF THE UNIDENTIFIED 
UR-144 PYROLYTIC PRODUCTS 
 
 
 
Mass spectrum for the UR-144 
 
 
 
 
Mass spectrum for the UR-144 Degradant 
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Chromatographic display (pyrogram; top) of the unidentified UR-144 pyrolytic product (UPP3) at 15.23 minutes; the mass spectra 
of the UPP3 has also been provided 
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Chromatographic display (pyrogram; top) of the unidentified UR-144 pyrolytic product (UPP4) at 16.78 minutes; the mass spectra 
of the UPP4 has also been provided 
